William Sandborn

Title(s)Recall Hcomp, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Fellowship1993Mayo Clinic
    Intern/Residency1990Loma Linda Univ Medical Center
    MD1987Loma Linda University
    BA1983Southern College

    Collapse Overview 

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Baseline Serum and Stool Microbiome Biomarkers Predict Clinical Efficacy and Tissue Molecular Response After Ritlecitinib Induction Therapy in Ulcerative Colitis. J Crohns Colitis. 2024 Sep 03; 18(9):1361-1370. Hassan-Zahraee M, Ye Z, Xi L, Dushin E, Lee J, Romatowski J, Leszczyszyn J, Danese S, Sandborn WJ, Banfield C, Gale JD, Peeva E, Longman RS, Hyde CL, Hung KE. PMID: 38141256; PMCID: PMC11369066.
      View in: PubMed   Mentions: 1     Fields:    
    2. Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis. J Crohns Colitis. 2024 Aug 06; 18(7):1091-1101. Ghosh S, Feagan BG, Ott E, Gasink C, Godwin B, Marano C, Miao Y, Ma T, Loftus EV, Sandborn WJ, Danese S, Abreu MT, Sands BE. PMID: 38310565; PMCID: PMC11302965.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    3. Pangenome comparison of Bacteroides fragilis genomospecies unveils genetic diversity and ecological insights. mSystems. 2024 Jul 23; 9(7):e0051624. Oles RE, Carrillo Terrazas M, Loomis LR, Hsu C-Y, Tribelhorn C, Belda-Ferre P, Ea AC, Bryant M, Young JA, Carrow HC, Sandborn WJ, Dulai PS, Sivagnanam M, Pride D, Knight R, Chu H. PMID: 38934546; PMCID: PMC11265264.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    4. Pathogenic Bacteroides fragilis strains can emerge from gut-resident commensals. bioRxiv. 2024 Jun 19. Oles RE, Terrazas MC, Loomis LR, Neal MJ, Paulchakrabarti M, Zuffa S, Hsu CY, Vasquez Ayala A, Lee MH, Tribelhorn C, Belda-Ferre P, Bryant M, Zemlin J, Young J, Dulai P, Sandborn WJ, Sivagnanam M, Raffatellu M, Pride D, Dorrestein PC, Zengler K, Choudhury B, Knight R, Chu H. PMID: 38948766; PMCID: PMC11213024.
      View in: PubMed   Mentions:
    5. Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C-reactive Protein: Results From the Phase 2 OASIS Trial. J Crohns Colitis. 2024 Jun 03; 18(6):885-894. Yarur AJ, Chiorean MV, Panés J, Jairath V, Zhang J, Rabbat CJ, Sandborn WJ, Vermeire S, Peyrin-Biroulet L. PMID: 38245818; PMCID: PMC11147797.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    6. A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn's disease in clinical practice. Nat Rev Gastroenterol Hepatol. 2024 Aug; 21(8):572-584. Bettenworth D, Baker ME, Fletcher JG, Jairath V, Lu C, Bemelman W, d'Haens G, d'Hoore A, Dignass A, Dotan I, Feakins R, Fleshner P, Ha C, Henderson G, Lyu R, Panes J, Rogler G, Mao R, Rimola J, Sandborn WJ, Ng SC, Siegmund B, Silverberg M, Taylor SA, Verstockt B, Gordon IO, Bruining DH, Feagan BG, Rieder F, Stenosis Therapy Anti-Fibrotic Research (STAR) Consortium. PMID: 38831007.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    7. Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease. J Crohns Colitis. 2024 May 31; 18(5):708-719. Vermeire S, Danese S, Sandborn WJ, Schreiber S, Hanauer S, D'Haens G, Nagy P, Thakur M, Bliss C, Cataldi F, Goetsch M, Gorelick KJ, Reinisch W. PMID: 38096402; PMCID: PMC11140626.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY). Gastroenterology. 2024 May 23. Hanauer SB, Sands BE, Schreiber S, Danese S, Klopocka M, Kierkus J, Kulynych R, Gonciarz M, Soltysiak A, Smolinski P, Sreckovic S, Valuyskikh E, Lahat A, Horynski M, Gasbarrini A, Osipenko M, Borzan V, Kowalski M, Saenko D, Sardinov R, Lee SJ, Kim S, Bae Y, Lee S, Lee S, Lee JH, Yang S, Lee J, Lee J, Kim JM, Park G, Sandborn WJ, Colombel JF. PMID: 38788861.
      View in: PubMed   Mentions:    Fields:    
    9. Reliability and Responsiveness of Clinical and Endoscopic Outcome Measures in Crohn's Disease. Inflamm Bowel Dis. 2024 Apr 25. Khanna R, Feagan BG, Zou G, Stitt LW, McDonald JWD, Bressler B, Panaccione R, Shackelton LM, VanViegen T, Loftus EV, Daperno M, Jairath V, D'Haens G, Sandborn WJ. PMID: 38661492.
      View in: PubMed   Mentions:    Fields:    
    10. Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis. Expert Rev Clin Pharmacol. 2024 Apr; 17(4):403-412. D'Haens G, Rosario M, Polhamus D, Dirks NL, Chen C, Kisfalvi K, Agboton C, Vermeire S, Feagan BG, Sandborn WJ. PMID: 38441048.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 studies. Eur J Gastroenterol Hepatol. 2024 Apr 01; 36(4):404-415. D'Haens G, Baert F, Danese S, Kobayashi T, Loftus EV, Sandborn WJ, Dornic Q, Lindner D, Kisfalvi K, Marins EG, Vermeire S. PMID: 38417060; PMCID: PMC10904001.
      View in: PubMed   Mentions: 1  Translation:Humans
    12. Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial. BMJ Open Gastroenterol. 2024 Feb 08; 11(1). Jairath V, Zou G, Wang Z, Adsul S, Colombel JF, D'Haens GR, Freire M, Moran GW, Peyrin-Biroulet L, Sandborn WJ, Sebastian S, Travis S, Vermeire S, Radulescu G, Sigler J, Hanžel J, Ma C, Sedano R, McFarlane SC, Arya N, Beaton M, Bossuyt P, Danese S, Green D, Harlan W, Horynski M, Klopocka M, Petroniene R, Silverberg MS, Wolanski L, Feagan BG. PMID: 38336367; PMCID: PMC10870790.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    13. Pangenome comparison of Bacteroides fragilis genomospecies unveil genetic diversity and ecological insights. bioRxiv. 2023 Dec 21. Oles RE, Terrazas MC, Loomis LR, Hsu CY, Tribelhorn C, Ferre PB, Ea A, Bryant M, Young J, Carrow HC, Sandborn WJ, Dulai P, Sivagnanam M, Pride D, Knight R, Chu H. PMID: 38187556; PMCID: PMC10769428.
      View in: PubMed   Mentions:
    14. Clinical Trial Design in Ulcerative Colitis: Interpreting Evolving Endpoints Based on Post Hoc Analyses of the Vedolizumab Phase 3 Trials GEMINI 1 and VISIBLE 1. Crohns Colitis 360. 2024 Jan; 6(1):otad076. Sandborn WJ, Sands BE, Uddin S, Qasim Khan RM, Sagar Mukherjee R. PMID: 38213631; PMCID: PMC10782208.
      View in: PubMed   Mentions:
    15. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial. Lancet Gastroenterol Hepatol. 2024 Feb; 9(2):133-146. Danese S, Panaccione R, Feagan BG, Afzali A, Rubin DT, Sands BE, Reinisch W, Panés J, Sahoo A, Terry NA, Chan D, Han C, Frustaci ME, Yang Z, Sandborn WJ, Hisamatsu T, Andrews JM, D'Haens GR, GALAXI-1 Study Group. PMID: 38104569.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    16. Efficacy and Safety of Ustekinumab for Ulcerative Colitis Through 4 Years: Final Results of the UNIFI Long-Term Maintenance Study. Am J Gastroenterol. 2024 05 01; 119(5):910-921. Afif W, Arasaradnam RP, Abreu MT, Danese S, Sandborn WJ, Miao Y, Zhang H, Panaccione R, Hisamatsu T, Scherl EJ, Leong RW, Rowbotham DS, Peyrin-Biroulet L, Sands BE, Marano C. PMID: 38095692; PMCID: PMC11062601.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    17. Qualitative and psychometric evaluation of the PROMIS®-Fatigue SF-7a scale to assess fatigue in patients with moderately to severely active inflammatory bowel disease. J Patient Rep Outcomes. 2023 Nov 14; 7(1):115. Feagan BG, Sandborn WJ, Sands BE, Liu Y, Vetter M, Mathias SD, Huang KG, Johanns J, Germinaro M, Han C. PMID: 37962770; PMCID: PMC10645698.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    18. Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study. Gastroenterology. 2023 12; 165(6):1443-1457. Peyrin-Biroulet L, Allegretti JR, Rubin DT, Bressler B, Germinaro M, Huang KG, Shipitofsky N, Zhang H, Wilson R, Han C, Feagan BG, Sandborn WJ, Panés J, Hisamatsu T, Lichtenstein GR, Sands BE, Dignass A, QUASAR Study Group. PMID: 37659673.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    19. Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE Studies. Crohns Colitis 360. 2023 Jul; 5(3):otad034. Sandborn WJ, Chen J, Kisfalvi K, Loftus EV, D'Haens G, Candela N, Lasch K, Wolf DC, Uddin SM, Danese S. PMID: 37636008; PMCID: PMC10449415.
      View in: PubMed   Mentions:
    20. Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study. Clin Transl Gastroenterol. 2023 07 01; 14(7):e00578. Steere B, Schmitz J, Powell N, Higgs R, Gottlieb K, Liu Y, Jia B, Tuttle JL, Sandborn WJ, Sands BE, D'Haens G, Reinisch W, Krishnan V. PMID: 36881820; PMCID: PMC10371316.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    21. Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2023 Jun 29; 388(26):2444-2455. D'Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, Krueger K, Laskowski J, Li X, Lissoos T, Milata J, Morris N, Arora V, Milch C, Sandborn W, Sands BE, LUCENT Study Group. PMID: 37379135.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    22. Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2024 01; 22(1):144-153.e2. Colombel JF, Sands BE, Gasink C, Yeager B, Adedokun OJ, Izanec J, Ma T, Gao LL, Lee SD, Targan SR, Ghosh S, Hanauer SB, Sandborn WJ. PMID: 37391056.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    23. A randomised, double-blind, placebo-controlled study of the LAG-3-depleting monoclonal antibody GSK2831781 in patients with active ulcerative colitis. Aliment Pharmacol Ther. 2023 08; 58(3):283-296. D'Haens G, Peyrin-Biroulet L, Marks DJB, Lisi E, Liefaard L, Beaton A, Srinivasan N, Bouma G, Prasad N, Cameron R, Kayali Z, Tarzi R, Hanauer S, Sandborn WJ. PMID: 37323059.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    24. Standardizing Scoring Conventions for Crohn's Disease Endoscopy: An International RAND/UCLA Appropriateness Study. Clin Gastroenterol Hepatol. 2023 10; 21(11):2938-2950.e6. Khanna R, Ma C, Hogan M, Zou G, Bessissow T, Bressler B, Colombel JF, Danese S, Daperno M, East JE, Hookey L, Loftus EV, McDonald JWD, Panaccione R, Peyrin-Biroulet L, Rutter M, Sands BE, Vermeire S, Rémillard J, McFarlane SC, Sandborn WJ, D'Haens GR, Feagan BG, Jairath V. PMID: 37308036.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme. J Crohns Colitis. 2023 Apr 03; 17(3):338-351. Sandborn WJ, D'Haens GR, Sands BE, Panaccione R, Ng SC, Lawendy N, Kulisek N, Modesto I, Guo X, Mundayat R, Su C, Vranic I, Panés J. PMID: 36124702; PMCID: PMC10069618.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    26. A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn's Disease. Inflamm Bowel Dis. 2023 04 03; 29(4):555-562. Holmer AK, Boland BS, Singh S, Neill J, Le H, Miralles A, Collins AE, Sandborn WJ, Dulai PS. PMID: 35704691; PMCID: PMC10069658.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    27. Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study. J Crohns Colitis. 2023 Mar 18; 17(2):211-220. Loftus EV, Vermeire S, Feagan BG, Le Brun FO, Oortwijn A, Moerch U, Sandborn WJ, Hibi T. PMID: 36006011; PMCID: PMC10024544.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    28. A Living Organoid Biobank of Crohn's Disease Patients Reveals Molecular Subtypes for Personalized Therapeutics. bioRxiv. 2023 Mar 13. Tindle C, Katkar GD, Fonseca AG, Taheri S, Lee J, Maity P, Sayed IM, Ibeawuchi SR, Vidales E, Pranadinata RF, Fuller M, Stec DL, Anandachar MS, Perry K, Le HN, Ear J, Boland BS, Sandborn WJ, Sahoo D, Das S, Ghosh P. PMID: 36993763; PMCID: PMC10054961.
      View in: PubMed   Mentions:
    29. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023 04 08; 401(10383):1159-1171. Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A, Ritter T, Baert F, Schreiber S, Sloan S, Cataldi F, Shan K, Rabbat CJ, Chiorean M, Wolf DC, Sands BE, D'Haens G, Danese S, Goetsch M, Feagan BG. PMID: 36871574.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    30. The ClC-2 Chloride Channel Activator, Lubiprostone, Improves Intestinal Barrier Function in Biopsies from Crohn's Disease but Not Ulcerative Colitis Patients. Pharmaceutics. 2023 Mar 02; 15(3). Park YS, Kang SB, Marchelletta RR, Penrose HM, Ruiter-Visser R, Jung B, Docherty MJ, Boland BS, Sandborn WJ, McCole DF. PMID: 36986672; PMCID: PMC10053841.
      View in: PubMed   Mentions: 2  
    31. Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial. Lancet Gastroenterol Hepatol. 2023 04; 8(4):307-320. Feagan BG, Sands BE, Sandborn WJ, Germinaro M, Vetter M, Shao J, Sheng S, Johanns J, Panés J, VEGA Study Group. PMID: 36738762.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    32. A tissue atlas of ulcerative colitis revealing evidence of sex-dependent differences in disease-driving inflammatory cell types and resistance to TNF inhibitor therapy. Sci Adv. 2023 01 20; 9(3):eadd1166. Mayer AT, Holman DR, Sood A, Tandon U, Bhate SS, Bodapati S, Barlow GL, Chang J, Black S, Crenshaw EC, Koron AN, Streett SE, Gambhir SS, Sandborn WJ, Boland BS, Hastie T, Tibshirani R, Chang JT, Nolan GP, Schürch CM, Rogalla S. PMID: 36662860; PMCID: PMC9858501.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    33. Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study. Clin Gastroenterol Hepatol. 2023 09; 21(10):2616-2628.e7. Sandborn WJ, Danese S, Leszczyszyn J, Romatowski J, Altintas E, Peeva E, Hassan-Zahraee M, Vincent MS, Reddy PS, Banfield C, Salganik M, Banerjee A, Gale JD, Hung KE. PMID: 36623678.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    34. High Discovery Rate of Duodenal and Gastric Eosinophilia in Patients With Unexplained Moderate-Severe Abdominal Symptoms: A Prospective US Multisite Study. Gastroenterology. 2023 04; 164(4):680-683.e2. Talley NJ, Peterson KA, Genta RM, Chang AT, Dellon ES, Sandborn WJ, 019 Study Team, Lacy BE, Chehade M, Hirano I, Gonsalves N, Lembo A, Schmitt CM, Rothenberg ME, Jain N, Pletneva MA, Turner KO, Youngblood BA. PMID: 36574864.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    35. Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program. Therap Adv Gastroenterol. 2022; 15:17562848221136331. Sandborn WJ, Sands BE, Vermeire S, Leung Y, Guo X, Modesto I, Su C, Wang W, Panés J. PMID: 36506749; PMCID: PMC9726836.
      View in: PubMed   Mentions: 3  
    36. Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study. Clin Gastroenterol Hepatol. 2023 08; 21(9):2359-2369.e5. Singh S, Kim J, Luo J, Paul P, Rudrapatna V, Park S, Zheng K, Syal G, Ha C, Fleshner P, McGovern D, Sauk JS, Limketkai B, Dulai PS, Boland BS, Eisenstein S, Ramamoorthy S, Melmed G, Mahadevan U, Sandborn WJ, Ohno-Machado L. PMID: 36343846.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    37. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn's disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2023 Jan; 8(1):43-55. Sandborn WJ, Panés J, Danese S, Sharafali Z, Hassanali A, Jacob-Moffatt R, Eden C, Daperno M, Valentine JF, Laharie D, Baía C, Atreya R, Panaccione R, Rydzewska G, Aguilar H, Vermeire S, BERGAMOT Study Group. PMID: 36240801.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    38. The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium. Am J Gastroenterol. 2023 02 01; 118(2):317-328. Johnson AM, Barsky M, Ahmed W, Zullow S, Galati J, Jairath V, Narula N, Peerani F, Click BH, Coburn ES, Dang TT, Gold S, Agrawal M, Garg R, Aggarwal M, Mohammad D, Halloran B, Kochhar GS, Todorowski H, Ud Din NM, Izanec J, Teeple A, Gasink C, Muser E, Ding Z, Swaminath A, Lakhani K, Hogan D, Datta S, Ungaro RC, Boland BS, Bohm M, Fischer M, Sagi S, Afzali A, Ullman T, Lawlor G, Baumgart DC, Chang S, Hudesman D, Lukin D, Scherl EJ, Colombel JF, Sands BE, Siegel CA, Regueiro M, Sandborn WJ, Bruining D, Kane S, Loftus EV, Dulai PS. PMID: 36191274.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    39. Population Pharmacokinetics and Exposure-Response Analyses of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease. Clin Ther. 2022 10; 44(10):1336-1355. Adedokun OJ, Xu Z, Gasink C, Kowalski K, Sandborn WJ, Feagan B. PMID: 36150926.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    40. ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension. Lancet Gastroenterol Hepatol. 2022 11; 7(11):1024-1035. Vermeire S, Sands BE, Tilg H, Tulassay Z, Kempinski R, Danese S, Bunganic I, Nitcheu J, Santo J, Scherrer D, Biguenet S, Ehrlich HJ, Steens JM, Gineste P, Sandborn WJ. PMID: 36075249.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    41. Reply. Gastroenterology. 2023 Jan; 164(1):166-168. D'Haens GR, Sandborn WJ. PMID: 36067821.
      View in: PubMed   Mentions:    Fields:    
    42. Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease. Inflamm Bowel Dis. 2022 09 01; 28(9):1321-1331. Hanzel J, Jairath V, De Cruz P, Guizzetti L, Shackelton LM, Bossuyt P, Duijvestein M, Dulai PS, Grossmann J, Hirten RP, Khanna R, Panes J, Peyrin-Biroulet L, Regueiro M, Rubin DT, Singh S, Stidham RW, Sandborn WJ, Feagan BG, D'Haens GR, Ma C. PMID: 34791254; PMCID: PMC9756946.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    43. Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2022 09 01; 28(9):1338-1347. Sandborn WJ, Armuzzi A, Liguori G, Irving PM, Sharara AI, Mundayat R, Lawendy N, Woolcott JC, Danese S. PMID: 34958359; PMCID: PMC9434448.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    44. Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension. J Crohns Colitis. 2022 Aug 30; 16(8):1222-1234. Abreu MT, Rowbotham DS, Danese S, Sandborn WJ, Miao Y, Zhang H, Tikhonov I, Panaccione R, Hisamatsu T, Scherl EJ, Leong RW, Arasaradnam RP, Afif W, Peyrin-Biroulet L, Sands BE, Marano C. PMID: 35239968; PMCID: PMC9426670.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    45. Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial. Am J Gastroenterol. 2023 01 01; 118(1):138-147. Danese S, Ferrante M, Feagan BG, Peyrin-Biroulet L, Hibi T, Sandborn WJ, Schreiber S, Ritter T, Loftus EV, Rogler G, Oortwijn A, Yun C, Le Brun FO, Dinoso J, Hsieh J, Vermeire S. PMID: 36113491; PMCID: PMC9810009.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    46. Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study. Gastroenterology. 2022 12; 163(6):1555-1568. Chen B, Zhong J, Li X, Pan F, Ding Y, Zhang Y, Chen H, Liu F, Zhang Z, Zhang L, Drozda R, Oliinyk O, Goh AH, Chen X, Sun X, Rubin DT, Sandborn WJ, Chen M. PMID: 35963369.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    47. Efficacy of Pharmacological Agents for Ulcerative Proctitis: A Systematic Literature Review. J Crohns Colitis. 2022 Jul 14; 16(6):922-930. Caron B, Sandborn WJ, Panaccione R, Schreiber S, Hart A, Solitano V, Danese S, Peyrin-Biroulet L. PMID: 34850857.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    48. Management of pouch neoplasia: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2022 09; 7(9):871-893. Kiran RP, Kochhar GS, Kariv R, Rex DK, Sugita A, Rubin DT, Navaneethan U, Hull TL, Ko HM, Liu X, Kachnic LA, Strong S, Iacucci M, Bemelman W, Fleshner P, Safyan RA, Kotze PG, D'Hoore A, Faiz O, Lo S, Ashburn JH, Spinelli A, Bernstein CN, Kane SV, Cross RK, Schairer J, McCormick JT, Farraye FA, Chang S, Scherl EJ, Schwartz DA, Bruining DH, Philpott J, Bentley-Hibbert S, Tarabar D, El-Hachem S, Sandborn WJ, Silverberg MS, Pardi DS, Church JM, Shen B. PMID: 35798022.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    49. CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. Gastroenterology. 2022 10; 163(4):950-964. CORE-IBD Collaborators, Ma C, Hanzel J, Panaccione R, Sandborn WJ, D'Haens GR, Ahuja V, Atreya R, Bernstein CN, Bossuyt P, Bressler B, Bryant RV, Cohen B, Colombel JF, Danese S, Dignass A, Dubinsky MC, Fleshner PR, Gearry RB, Hanauer SB, Hart A, Kotze PG, Kucharzik T, Lakatos PL, Leong RW, Magro F, Panés J, Peyrin-Biroulet L, Ran Z, Regueiro M, Singh S, Spinelli A, Steinhart AH, Travis SP, van der Woude CJ, Yacyshyn B, Yamamoto T, Allez M, Bemelman WA, Lightner AL, Louis E, Rubin DT, Scherl EJ, Siegel CA, Silverberg MS, Vermeire S, Parker CE, McFarlane SC, Guizzetti L, Smith MI, Vande Casteele N, Feagan BG, Jairath V. PMID: 35788348.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    50. Long-Term Safety and Efficacy of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Monoclonal Antibody Ontamalimab (SHP647) for the Treatment of Crohn's Disease: The OPERA II Study. Inflamm Bowel Dis. 2022 07 01; 28(7):1034-1044. D'Haens GR, Reinisch W, Lee SD, Tarabar D, Louis E, Klopocka M, Klaus J, Schreiber S, Il Park D, Hébuterne X, Nagy P, Cataldi F, Martin SW, Nayak S, Banerjee A, Gorelick KJ, Sandborn WJ. PMID: 34427633; PMCID: PMC9247846.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    51. Clinical, Endoscopic, and Safety Placebo Rates in Induction and Maintenance Trials of Crohn's Disease: Meta-Analysis of Randomised Controlled Trials. J Crohns Colitis. 2022 Jun 24; 16(5):717-736. Almradi A, Sedano R, Hogan M, Zou GY, MacDonald JK, Parker CE, Hanzel J, Crowley E, Singh S, D'Haens G, Sandborn WJ, Feagan BG, Ma C, Jairath V. PMID: 34758084.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    52. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet. 2022 06 11; 399(10342):2200-2211. Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ, SEAVUE Study Group. PMID: 35691323.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    53. Simplified Machine Learning Models Can Accurately Identify High-Need High-Cost Patients With Inflammatory Bowel Disease. Clin Transl Gastroenterol. 2022 07 01; 13(7):e00507. Nguyen NH, Patel S, Gabunilas J, Qian AS, Cecil A, Jairath V, Sandborn WJ, Ohno-Machado L, Chen PL, Singh S. PMID: 35905414; PMCID: PMC10476830.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    54. Effect of Obesity on Risk of Hospitalization, Surgery, and Serious Infection in Biologic-Treated Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study. Am J Gastroenterol. 2022 10 01; 117(10):1639-1647. Gu P, Luo J, Kim J, Paul P, Limketkai B, Sauk JS, Park S, Parekh N, Zheng K, Rudrapatna V, Syal G, Ha C, McGovern DP, Melmed GY, Fleshner P, Eisenstein S, Ramamoorthy S, Dulai PS, Boland BS, Grunvald E, Mahadevan U, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 35973139.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    55. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022 05 28; 399(10340):2015-2030. D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. PMID: 35644154.
      View in: PubMed   Mentions: 73     Fields:    Translation:Humans
    56. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022 05 28; 399(10340):2031-2046. Ferrante M, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, D'Haens G. PMID: 35644155.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCTClinical Trials
    57. Effectiveness and Safety of Biologic Therapy in Hispanic Vs Non-Hispanic Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study. Clin Gastroenterol Hepatol. 2023 01; 21(1):173-181.e5. Nguyen NH, Luo J, Paul P, Kim J, Syal G, Ha C, Rudrapatna V, Park S, Parekh N, Zheng K, Sauk JS, Limketkai B, Fleshner P, Eisenstein S, Ramamoorthy S, Melmed G, Dulai PS, Boland BS, Mahadevan U, Sandborn WJ, Ohno-Machado L, McGovern D, Singh S. PMID: 35644340; PMCID: PMC9701245.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    58. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022 06 04; 399(10341):2113-2128. Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, Hébuterne X, D'Haens G, Nakase H, Panés J, Higgins PDR, Juillerat P, Lindsay JO, Loftus EV, Sandborn WJ, Reinisch W, Chen MH, Sanchez Gonzalez Y, Huang B, Xie W, Liu J, Weinreich MA, Panaccione R. PMID: 35644166.
      View in: PubMed   Mentions: 109     Fields:    Translation:HumansCTClinical Trials
    59. Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for 1-year Endoscopic Remission in Moderate to Severe Crohn's Disease. J Crohns Colitis. 2022 May 10; 16(4):616-624. Narula N, Wong ECL, Colombel JF, Sandborn WJ, Ferrante M, Marshall JK, Reinisch W, Dulai PS. PMID: 34664635; PMCID: PMC9274823.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    60. A Framework for Clinical Trials of Neurobiological Interventions That Target the Gut-Brain Axis in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2022 05 04; 28(5):788-800. Tse CS, Singh S, Sandborn WJ. PMID: 34244749.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    61. Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies. Clin Pharmacol Ther. 2022 07; 112(1):90-100. Mukherjee A, Tsuchiwata S, Nicholas T, Cook JA, Modesto I, Su C, D'Haens GR, Sandborn WJ. PMID: 35380740; PMCID: PMC9322343.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    62. Real-world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure-response relationship of vedolizumab in inflammatory bowel disease: ERELATE Study. Aliment Pharmacol Ther. 2022 08; 56(3):463-476. Vande Casteele N, Sandborn WJ, Feagan BG, Vermeire S, Dulai PS, Yarur A, Roblin X, Ben-Horin S, Dotan I, Osterman MT, Rosario M, Osborn TM, Panes J, Lindner D, Agboton C. PMID: 35474325.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    63. Disease Activity Indices for Pouchitis: A Systematic Review. Inflamm Bowel Dis. 2022 03 30; 28(4):622-638. Sedano R, Nguyen TM, Almradi A, Rieder F, Parker CE, Shackelton LM, D'Haens G, Sandborn WJ, Feagan BG, Ma C, Jairath V. PMID: 34180986; PMCID: PMC8972820.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    64. Machine Learning-based Prediction Models for Diagnosis and Prognosis in Inflammatory Bowel Diseases: A Systematic Review. J Crohns Colitis. 2022 Mar 14; 16(3):398-413. Nguyen NH, Picetti D, Dulai PS, Jairath V, Sandborn WJ, Ohno-Machado L, Chen PL, Singh S. PMID: 34492100; PMCID: PMC8919806.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    65. The Relationship Between Endoscopic and Clinical Recurrence in Postoperative Crohn's Disease: A Systematic Review and Meta-analysis. J Crohns Colitis. 2022 Mar 14; 16(3):490-499. Ble A, Renzulli C, Cenci F, Grimaldi M, Barone M, Sedano R, Chang J, Nguyen TM, Hogan M, Zou G, MacDonald JK, Ma C, Sandborn WJ, Feagan BG, Merlo Pich E, Jairath V. PMID: 34508572; PMCID: PMC8919832.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    66. Association Between Proposed Definitions of Clinical Remission/Response and Well-Being in Patients With Crohn's Disease. J Crohns Colitis. 2022 Mar 14; 16(3):444-451. Sandborn WJ, Lewis JD, Panes J, Loftus EV, D'Haens G, Yu Z, Huang B, Lacerda AP, Pangan AL, Feagan BG. PMID: 34546360; PMCID: PMC8919823.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    67. Artificial intelligence-rationalized balanced PPARα/γ dual agonism resets dysregulated macrophage processes in inflammatory bowel disease. Commun Biol. 2022 03 14; 5(1):231. Katkar GD, Sayed IM, Anandachar MS, Castillo V, Vidales E, Toobian D, Usmani F, Sawires JR, Leriche G, Yang J, Sandborn WJ, Das S, Sahoo D, Ghosh P. PMID: 35288651; PMCID: PMC8921270.
      View in: PubMed   Mentions: 5  Translation:HumansAnimalsCells
    68. Trends in U.S. Health Care Spending on Inflammatory Bowel Diseases, 1996-2016. Inflamm Bowel Dis. 2022 03 02; 28(3):364-372. Singh S, Qian AS, Nguyen NH, Ho SKM, Luo J, Jairath V, Sandborn WJ, Ma C. PMID: 33988697; PMCID: PMC8889287.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    69. Editorial: protecting hypoxia-inducible factor 1a and gut integrity with GB004-a promising therapeutic approach for ulcerative colitis? Authors' reply. Aliment Pharmacol Ther. 2022 03; 55(6):735-736. Danese S, Levesque BG, Feagan BG, Jucov A, Bhandari BR, Pai RK, Meadows KT, Kirby BJ, Bruey JM, Olson A, Osterhout R, Van Biene C, Ford J, Aranda R, Raghupathi K, Sandborn WJ. PMID: 35245951.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    70. Net Remission Rates with Biologic Treatment in Crohn's Disease: A Reappraisal of the Clinical Trial Data. Clin Gastroenterol Hepatol. 2023 05; 21(5):1348-1350. Kayal M, Ungaro RC, Bader G, Colombel JF, Sandborn WJ, Stalgis C. PMID: 35245701.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    71. Design of Clinical Trials for Mild to Moderate Crohn's Disease. Gastroenterology. 2022 06; 162(7):1800-1814.e1. Hanzel J, Ma C, Jairath V, IBD Trial Design Group. PMID: 35240140.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    72. Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results. Gastroenterology. 2022 06; 162(7):1891-1910. Panés J, Colombel JF, D'Haens GR, Schreiber S, Panaccione R, Peyrin-Biroulet L, Loftus EV, Danese S, Tanida S, Okuyama Y, Louis E, Armuzzi A, Ferrante M, Vogelsang H, Hibi T, Watanabe M, Lefebvre J, Finney-Hayward T, Sanchez Gonzalez Y, Doan TT, Mostafa NM, Ikeda K, Xie W, Huang B, Petersson J, Kalabic J, Robinson AM, Sandborn WJ. PMID: 35227777.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    73. Systematic Review and Meta-Analysis: Clinical, Endoscopic, Histological and Safety Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. J Crohns Colitis. 2022 Feb 23; 16(2):224-243. Sedano R, Hogan M, Nguyen TM, Chang J, Zou GY, Macdonald JK, Vande Casteele N, Hanzel J, Crowley E, Battat R, Dulai PS, Singh S, D'Haens G, Sandborn W, Feagan BG, Ma C, Jairath V. PMID: 34309658.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    74. IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. Clin Gastroenterol Hepatol. 2022 11; 20(11):2619-2627.e1. Caron B, Abreu MT, Siegel CA, Panaccione R, Sands BE, Dignass A, Turner D, Dotan I, Hart AL, Ahuja V, Allez M, Ananthakrishnan AN, Ghosh S, Griffiths AM, Halfvarson J, Kaser A, Kotze PG, Koutroubakis IE, Lakatos PL, Levine A, Lewis JD, Magro F, Mantzaris GJ, O'Morain C, Ran Z, Reinisch W, Rogler G, Sachar DB, Siegmund B, Silverberg MS, Sood A, Spinelli A, Steinwurz F, Tysk C, Yamamoto-Furusho JK, Schreiber S, Rubin DT, Sandborn WJ, Danese S, Peyrin-Biroulet L. PMID: 35189386.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    75. Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study. Gastroenterology. 2022 05; 162(6):1650-1664.e8. Sandborn WJ, D'Haens GR, Reinisch W, Panés J, Chan D, Gonzalez S, Weisel K, Germinaro M, Frustaci ME, Yang Z, Adedokun OJ, Han C, Panaccione R, Hisamatsu T, Danese S, Rubin DT, Sands BE, Afzali A, Andrews JM, Feagan BG, GALAXI-1 Investigators. PMID: 35134323.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    76. Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results. Gastroenterology. 2022 06; 162(7):1876-1890. D'Haens GR, Sandborn WJ, Loftus EV, Hanauer SB, Schreiber S, Peyrin-Biroulet L, Panaccione R, Panés J, Baert F, Colombel JF, Ferrante M, Louis E, Armuzzi A, Zhou Q, Goteti VS, Mostafa NM, Doan TT, Petersson J, Finney-Hayward T, Song AP, Robinson AM, Danese S. PMID: 35122766.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    77. Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. Lancet Gastroenterol Hepatol. 2022 02; 7(2):171-185. Papamichael K, Afif W, Drobne D, Dubinsky MC, Ferrante M, Irving PM, Kamperidis N, Kobayashi T, Kotze PG, Lambert J, Noor NM, Roblin X, Roda G, Vande Casteele N, Yarur AJ, Arebi N, Danese S, Paul S, Sandborn WJ, Vermeire S, Cheifetz AS, Peyrin-Biroulet L, International Consortium for Therapeutic Drug Monitoring. PMID: 35026171; PMCID: PMC10187071.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    78. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. J Crohns Colitis. 2022 Jan 28; 16(1):27-38. Vermeire S, D'Haens G, Baert F, Danese S, Kobayashi T, Loftus EV, Bhatia S, Agboton C, Rosario M, Chen C, Zhang W, Kisfalvi K, Sandborn WJ. PMID: 34402887; PMCID: PMC8797168.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    79. Multi-omics analyses of the ulcerative colitis gut microbiome link Bacteroides vulgatus proteases with disease severity. Nat Microbiol. 2022 02; 7(2):262-276. Mills RH, Dulai PS, Vázquez-Baeza Y, Sauceda C, Daniel N, Gerner RR, Batachari LE, Malfavon M, Zhu Q, Weldon K, Humphrey G, Carrillo-Terrazas M, Goldasich LD, Bryant M, Raffatellu M, Quinn RA, Gewirtz AT, Chassaing B, Chu H, Sandborn WJ, Dorrestein PC, Knight R, Gonzalez DJ. PMID: 35087228; PMCID: PMC8852248.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansAnimalsCells
    80. Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. Lancet Gastroenterol Hepatol. 2022 03; 7(3):254-261. Guillo L, Abreu M, Panaccione R, Sandborn WJ, Azevedo VF, Gensler L, Moghaddam B, Ahuja V, Ali SA, Allez M, Ananthakrishnan AN, Bhattacharya A, Dubinsky M, Griffiths A, Hart A, Korelitz B, Kotze PG, Koutroubakis IE, Lakatos PL, Lindsay JO, Magro F, Mantzaris GJ, Ng SC, O'Morain C, Panés J, Parigi T, Ran Z, Rogler G, Rubin DT, Sachar DB, Siegmund B, Steinwurz F, Tysk C, Vavricka S, Verstraete SG, Brezin AP, Haemel AK, Dignass A, Sands BE, Danese S, Peyrin-Biroulet L. PMID: 35051383.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    81. Ozanimod for Ulcerative Colitis. Reply. N Engl J Med. 2022 01 13; 386(2):194-195. Sandborn WJ, Danese S. PMID: 35020995.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    82. Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1α stabiliser, for treatment of ulcerative colitis. Aliment Pharmacol Ther. 2022 02; 55(4):401-411. Danese S, Levesque BG, Feagan BG, Jucov A, Bhandari BR, Pai RK, Taylor Meadows K, Kirby BJ, Bruey JM, Olson A, Osterhout R, Van Biene C, Ford J, Aranda R, Raghupathi K, Sandborn WJ. PMID: 35014040; PMCID: PMC9305136.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    83. Design of Clinical Trials for Mild to Moderate Ulcerative Colitis. Gastroenterology. 2022 04; 162(4):1005-1018. Sedano R, Jairath V, Ma C, IBD Trial Design Group. PMID: 34998800.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    84. Digital Health Technologies for Remote Monitoring and Management of Inflammatory Bowel Disease: A Systematic Review. Am J Gastroenterol. 2022 01 01; 117(1):78-97. Nguyen NH, Martinez I, Atreja A, Sitapati AM, Sandborn WJ, Ohno-Machado L, Singh S. PMID: 34751673; PMCID: PMC8987011.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    85. A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn's Disease. BioDrugs. 2022 Jan; 36(1):85-93. Lefevre PLC, Dulai PS, Wang Z, Guizzetti L, Feagan BG, Pop A, Yassine M, Shackelton LM, Jairath V, Sandborn WJ, Vande Casteele N. PMID: 34951696; PMCID: PMC9826742.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    86. Class Ib MHC-Mediated Immune Interactions Play a Critical Role in Maintaining Mucosal Homeostasis in the Mammalian Large Intestine. Immunohorizons. 2021 12 15; 5(12):953-971. Dasgupta S, Maricic I, Tang J, Wandro S, Weldon K, Carpenter CS, Eckmann L, Rivera-Nieves J, Sandborn W, Knight R, Dorrestein P, Swafford AD, Kumar V. PMID: 34911745; PMCID: PMC10026853.
      View in: PubMed   Mentions:    Fields:    Translation:AnimalsCells
    87. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol. 2021; 14:17562848211059954. Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, Danese S, Ghosh S. PMID: 34917173; PMCID: PMC8669878.
      View in: PubMed   Mentions: 8  
    88. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther. 2022 02; 55(4):464-478. Sandborn WJ, Lawendy N, Danese S, Su C, Loftus EV, Hart A, Dotan I, Damião AOMC, Judd DT, Guo X, Modesto I, Wang W, Panés J. PMID: 34854095; PMCID: PMC9300081.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    89. No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn's Disease Treated with Anti-metabolite Therapy. Dig Dis Sci. 2022 07; 67(7):3115-3123. Picetti D, Kim J, Zhu W, Sandborn WJ, Jairath V, Singh S. PMID: 34797442; PMCID: PMC9117569.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    90. Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. BioDrugs. 2021 Nov; 35(6):715-733. Bots SJ, Parker CE, Brandse JF, Löwenberg M, Feagan BG, Sandborn WJ, Jairath V, D'Haens G, Vande Casteele N. PMID: 34797516; PMCID: PMC9826743.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    91. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol. 2022 02; 7(2):128-140. Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus EV, Ostad-Saffari E, Scalori A, Oh YS, Tole S, Chai A, Pulley J, Lacey S, Sandborn WJ, HICKORY Study Group. PMID: 34798039.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    92. Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2022 01; 7(1):69-95. Shen B, Kochhar GS, Rubin DT, Kane SV, Navaneethan U, Bernstein CN, Cross RK, Sugita A, Schairer J, Kiran RP, Fleshner P, McCormick JT, D'Hoore A, Shah SA, Farraye FA, Kariv R, Liu X, Rosh J, Chang S, Scherl E, Schwartz DA, Kotze PG, Bruining DH, Philpott J, Abraham B, Segal J, Sedano R, Kayal M, Bentley-Hibbert S, Tarabar D, El-Hachem S, Sehgal P, Picoraro JA, Vermeire S, Sandborn WJ, Silverberg MS, Pardi DS. PMID: 34774224.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansPHPublic Health
    93. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease. Gastroenterology. 2022 02; 162(2):495-508. Sands BE, Peyrin-Biroulet L, Kierkus J, Higgins PDR, Fischer M, Jairath V, Hirai F, D'Haens G, Belin RM, Miller D, Gomez-Valderas E, Naegeli AN, Tuttle JL, Pollack PF, Sandborn WJ. PMID: 34748774.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    94. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021 12; 6(12):1002-1014. Singh S, Murad MH, Fumery M, Sedano R, Jairath V, Panaccione R, Sandborn WJ, Ma C. PMID: 34688373; PMCID: PMC8933137.
      View in: PubMed   Mentions: 77     Fields:    Translation:Humans
    95. Frailty and Risk of Serious Infections in Biologic-treated Patients With Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2021 10 18; 27(10):1626-1633. Singh S, Heien HC, Sangaralingham L, Shah ND, Lai JC, Sandborn WJ, Moore AA. PMID: 33325507; PMCID: PMC8522787.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    96. Agreement between local and central reading of endoscopic disease activity in ulcerative colitis: results from the tofacitinib OCTAVE trials. Aliment Pharmacol Ther. 2021 12; 54(11-12):1442-1453. Feagan BG, Khanna R, Sandborn WJ, Vermeire S, Reinisch W, Su C, Salese L, Fan H, Paulissen J, Woodworth DA, Niezychowski W, Sands BE. PMID: 34614208; PMCID: PMC9291991.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    97. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2021 09 30; 385(14):1280-1291. Sandborn WJ, Feagan BG, D'Haens G, Wolf DC, Jovanovic I, Hanauer SB, Ghosh S, Petersen A, Hua SY, Lee JH, Charles L, Chitkara D, Usiskin K, Colombel JF, Laine L, Danese S, True North Study Group. PMID: 34587385.
      View in: PubMed   Mentions: 142     Fields:    Translation:HumansCTClinical Trials
    98. Correction to: Understanding Determinants of Patient Preferences Between Stool Tests and Colonoscopy for the Assessment of Disease Activity in Inflammatory Bowel Disease. Dig Dis Sci. 2021 Sep; 66(9):3216. Barsky M, Meserve J, Le H, Collins A, Singh S, Boland B, Sandborn WJ, Dulai PS. PMID: 33555517.
      View in: PubMed   Mentions:    Fields:    
    99. PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis. Gastroenterology. 2021 12; 161(6):1853-1864.e10. Sandborn WJ, Mattheakis LC, Modi NB, Pugatch D, Bressler B, Lee S, Bhandari R, Kanwar B, Shames R, D'Haens G, Schreiber S, Danese S, Feagan B, Pai RK, Liu DY, Gupta S. PMID: 34474038.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    100. Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2021 10; 6(10):826-849. Shen B, Kochhar GS, Kariv R, Liu X, Navaneethan U, Rubin DT, Cross RK, Sugita A, D'Hoore A, Schairer J, Farraye FA, Kiran RP, Fleshner P, Rosh J, Shah SA, Chang S, Scherl E, Pardi DS, Schwartz DA, Kotze PG, Bruining DH, Kane SV, Philpott J, Abraham B, Segal J, Sedano R, Kayal M, Bentley-Hibbert S, Tarabar D, El-Hachem S, Sehgal P, McCormick JT, Picoraro JA, Silverberg MS, Bernstein CN, Sandborn WJ, Vermeire S. PMID: 34416186.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    101. Systematic Review and Meta-Analysis: Risk of Hospitalization in Patients with Ulcerative Colitis and Crohn's Disease in Population-Based Cohort Studies. Dig Dis Sci. 2022 06; 67(6):2451-2461. Tsai L, Nguyen NH, Ma C, Prokop LJ, Sandborn WJ, Singh S. PMID: 34379220; PMCID: PMC8831664.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    102. A Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Crohn's Disease. Am J Gastroenterol. 2021 08 01; 116(8):1709-1719. Dulai PS, Jairath V, Narula N, Wong E, Kochhar GS, Colombel JF, Sandborn WJ. PMID: 34587127; PMCID: PMC8481677.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    103. Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Crohn Disease: A Theoretical Construct to Apply Pharmacokinetics and Guidelines to Clinical Practice. Inflamm Bowel Dis. 2021 07 27; 27(8):1346-1355. Vande Casteele N, Feagan BG, Wolf DC, Pop A, Yassine M, Horst SN, Ritter TE, Sandborn WJ. PMID: 33051647; PMCID: PMC8314098.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    104. Histologic Remission Is Associated With Lower Risk of Treatment Failure in Patients With Crohn Disease in Endoscopic Remission. Inflamm Bowel Dis. 2021 07 27; 27(8):1277-1284. Yoon H, Jangi S, Dulai PS, Boland BS, Jairath V, Feagan BG, Sandborn WJ, Singh S. PMID: 33236763; PMCID: PMC8314112.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    105. Disease- and Treatment-related Complications in Older Patients With Inflammatory Bowel Diseases: Comparison of Adult-onset vs Elderly-onset Disease. Inflamm Bowel Dis. 2021 07 27; 27(8):1215-1223. Rozich JJ, Luo J, Dulai PS, Collins AE, Pham L, Boland BS, Sandborn WJ, Singh S. PMID: 33252124; PMCID: PMC8314101.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    106. Artificial intelligence guided discovery of a barrier-protective therapy in inflammatory bowel disease. Nat Commun. 2021 07 12; 12(1):4246. Sahoo D, Swanson L, Sayed IM, Katkar GD, Ibeawuchi SR, Mittal Y, Pranadinata RF, Tindle C, Fuller M, Stec DL, Chang JT, Sandborn WJ, Das S, Ghosh P. PMID: 34253728; PMCID: PMC8275683.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimals
    107. Obesity Is Not Associated With an Increased Risk of Serious Infections in Biologic-Treated Patients With Inflammatory Bowel Diseases. Clin Transl Gastroenterol. 2021 07 06; 12(7):e00380. Singh S, Heien HC, Sangaralingham L, Shah ND, Sandborn WJ. PMID: 34228004; PMCID: PMC8260899.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    108. Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial. J Crohns Colitis. 2021 Jul 05; 15(7):1130-1141. Vermeire S, Su C, Lawendy N, Kobayashi T, Sandborn WJ, Rubin DT, Modesto I, Gardiner S, Kulisek N, Zhang H, Wang W, Panés J. PMID: 33290538; PMCID: PMC8256630.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    109. Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. J Crohns Colitis. 2021 Jul 05; 15(7):1120-1129. Sandborn WJ, Feagan BG, Hanauer S, Vermeire S, Ghosh S, Liu WJ, Petersen A, Charles L, Huang V, Usiskin K, Wolf DC, D'Haens G. PMID: 33438008; PMCID: PMC8256627.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    110. Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study. J Crohns Colitis. 2021 Jun 22; 15(6):950-959. Vermeire S, Chiorean M, Panés J, Peyrin-Biroulet L, Zhang J, Sands BE, Lazin K, Klassen P, Naik SU, Cabell CH, Sandborn WJ. PMID: 33475734; PMCID: PMC8218705.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    111. Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II. J Crohns Colitis. 2021 Jun 22; 15(6):938-949. Reinisch W, Sandborn WJ, Danese S, Hébuterne X, Klopocka M, Tarabar D, Vanásek T, Greguš M, Hellstern PA, Kim JS, Sparrow MP, Gorelick KJ, Hoy M, Goetsch M, Bliss C, Gupta C, Cataldi F, Vermeire S. PMID: 33599720; PMCID: PMC8218706.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    112. National Estimates of Financial Hardship From Medical Bills and Cost-related Medication Nonadherence in Patients With Inflammatory Bowel Diseases in the United States. Inflamm Bowel Dis. 2021 06 15; 27(7):1068-1078. Nguyen NH, Khera R, Dulai PS, Boland BS, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 33051681; PMCID: PMC8205631.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    113. Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies. Inflamm Bowel Dis. 2021 06 15; 27(7):994-1007. Sandborn WJ, Feagan BG, Danese S, O'Brien CD, Ott E, Marano C, Baker T, Zhou Y, Volger S, Tikhonov I, Gasink C, Sands BE, Ghosh S. PMID: 32964215; PMCID: PMC8205635.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    114. Burden and Outcomes of Fragmentation of Care in Hospitalized Patients With Inflammatory Bowel Diseases: A Nationally Representative Cohort. Inflamm Bowel Dis. 2021 06 15; 27(7):1026-1034. Nguyen NH, Luo J, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 32944753; PMCID: PMC8205632.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    115. Patient-Reported Outcomes and Risk of Hospitalization and Readmission in Patients with Inflammatory Bowel Diseases. Dig Dis Sci. 2022 06; 67(6):2039-2048. Nguyen NH, Zhang X, Long MD, Sandborn WJ, Kappelman MD, Singh S. PMID: 34110539; PMCID: PMC8986995.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    116. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021 06 19; 397(10292):2372-2384. Feagan BG, Danese S, Loftus EV, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempinski R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L. PMID: 34090625.
      View in: PubMed   Mentions: 99     Fields:    Translation:HumansCTClinical Trials
    117. Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases. Dig Dis Sci. 2022 06; 67(6):2510-2516. Singh S, Heien HC, Sangaralingham L, Shah ND, Sandborn WJ. PMID: 34085174; PMCID: PMC8933138.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    118. International consensus to standardise histopathological scoring for small bowel strictures in Crohn's disease. Gut. 2022 03; 71(3):479-486. Gordon IO, Bettenworth D, Bokemeyer A, Srivastava A, Rosty C, de Hertogh G, Robert ME, Valasek MA, Mao R, Li J, Harpaz N, Borralho P, Pai RK, Odze R, Feakins R, Parker CE, Guizzetti L, Nguyen T, Shackelton LM, Sandborn WJ, Jairath V, Baker M, Bruining D, Fletcher JG, Feagan BG, Pai RK, Rieder F, Stenosis Therapy and Anti-Fibrotic Research (STAR) Consortium. PMID: 33952604; PMCID: PMC8903083.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    119. Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group. Lancet Gastroenterol Hepatol. 2021 06; 6(6):482-497. Shen B, Kochhar GS, Navaneethan U, Cross RK, Farraye FA, Iacucci M, Schwartz DA, Gonzalez-Lama Y, Schairer J, Kiran RP, Kotze PG, Kobayashi T, Bortlik M, Liu X, Levy AN, González Suárez B, Tang SJ, Coelho-Prabhu N, Lukas M, Bruining DH, El-Hachem S, Charles RJ, Chen Y, Sood A, Mao R, Loras C, Dulai PS, Picoraro JA, Chiorean M, Lukas M, Shergill A, Silverberg MS, Sandborn WJ, Bernstein CN. PMID: 33872568.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    120. Early Combined Immunosuppression May Be More Effective for Reducing Complications in Isolated Colonic- vs Ileal-Dominant Crohn Disease. Inflamm Bowel Dis. 2021 04 15; 27(5):639-646. Dulai PS, Jairath V, Zou G, Stitt LW, Khanna R, Sandborn WJ, Feagan BG, Singh S. PMID: 32592481; PMCID: PMC8243599.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    121. Gastrointestinal Surgery for Inflammatory Bowel Disease Persistently Lowers Microbiome and Metabolome Diversity. Inflamm Bowel Dis. 2021 04 15; 27(5):603-616. Fang X, Vázquez-Baeza Y, Elijah E, Vargas F, Ackermann G, Humphrey G, Lau R, Weldon KC, Sanders JG, Panitchpakdi M, Carpenter C, Jarmusch AK, Neill J, Miralles A, Dulai P, Singh S, Tsai M, Swafford AD, Smarr L, Boyle DL, Palsson BO, Chang JT, Dorrestein PC, Sandborn WJ, Knight R, Boland BS. PMID: 33026068; PMCID: PMC8047854.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    122. Risk of Relapse in Patients With Ulcerative Colitis With Persistent Endoscopic Healing: A Durable Treatment Endpoint. J Crohns Colitis. 2021 Apr 06; 15(4):567-574. Jangi S, Holmer AK, Dulai PS, Boland BS, Collins AE, Pham L, Sandborn WJ, Singh S. PMID: 32914194; PMCID: PMC8023862.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    123. Advances in the Comprehensive Management of Postoperative Crohn's Disease. Clin Gastroenterol Hepatol. 2022 07; 20(7):1436-1449. Battat R, Sandborn WJ. PMID: 33819666.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    124. Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis-authors' reply. Aliment Pharmacol Ther. 2021 04; 53(8):957-958. Jangi S, Yoon H, Dulai P, Valasek M, Boland B, Jairath V, Feagan B, Sandborn W, Singh S. PMID: 33745174.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    125. The Guide to Guidelines in Ulcerative Colitis: Interpretation and Appropriate Use in Clinical Practice. Gastroenterol Hepatol (N Y). 2021 Apr; 17(4 Suppl 4):3-13. Sandborn WJ, Feagan BG, Hanauer SB, Lichtenstein GR. PMID: 34135718; PMCID: PMC8191814.
      View in: PubMed   Mentions: 6  
    126. Drug development for ulcerative proctitis: current concepts. Gut. 2021 07; 70(7):1203-1209. Caron B, Sandborn WJ, Schreiber S, Panaccione R, Danese S, Peyrin-Biroulet L. PMID: 33789968.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    127. Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD). Gut. 2022 06; 71(6):1078-1087. Narula N, Wong ECL, Colombel JF, Sandborn WJ, Marshall JK, Daperno M, Reinisch W, Dulai PS. PMID: 33766910.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    128. An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials. Aliment Pharmacol Ther. 2021 05; 53(10):1108-1117. Sedano R, Ma C, Pai RK, D' Haens G, Guizzetti L, Shackelton LM, Remillard J, Gionchetti P, Gordon IO, Holubar S, Kayal M, Lauwers GY, Pai RK, Pardi DS, Samaan MA, Schaeffer DF, Shen B, Silverberg MS, Feagan BG, Sandborn WJ, Jairath V. PMID: 33735522.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    129. Paternal Exposure to Immunosuppressive and/or Biologic Agents and Birth Outcomes in Patients With Immune-Mediated Inflammatory Diseases. Gastroenterology. 2021 07; 161(1):107-115.e3. Meserve J, Luo J, Zhu W, Veeravalli N, Bandoli G, Chambers CD, Singh AG, Boland BS, Sandborn WJ, Mahadevan U, Singh S. PMID: 33744307; PMCID: PMC8238837.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansPHPublic Health
    130. Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status. Clin Gastroenterol Hepatol. 2022 03; 20(3):591-601.e8. Sandborn WJ, Peyrin-Biroulet L, Sharara AI, Su C, Modesto I, Mundayat R, Gunay LM, Salese L, Sands BE. PMID: 33684552.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    131. Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2022 02; 20(2):e74-e88. Singh S, Heien HC, Herrin J, Dulai PS, Sangaralingham L, Shah ND, Sandborn WJ. PMID: 33640480; PMCID: PMC8384969.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    132. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021 04; 160(5):1570-1583. Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, Bettenworth D, Sandborn WJ, Sands BE, Reinisch W, Schölmerich J, Bemelman W, Danese S, Mary JY, Rubin D, Colombel JF, Peyrin-Biroulet L, Dotan I, Abreu MT, Dignass A, International Organization for the Study of IBD. PMID: 33359090.
      View in: PubMed   Mentions: 552     Fields:    Translation:Humans
    133. Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI Trial. Clin Gastroenterol Hepatol. 2022 03; 20(3):578-590.e4. Sandborn WJ, Rebuck R, Wang Y, Zou B, Adedokun OJ, Gasink C, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJS, Colombel JF, Feagan BG, Lynch JP. PMID: 33618023; PMCID: PMC8374005.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    134. An International Consensus to Standardize Integration of Histopathology in Ulcerative Colitis Clinical Trials. Gastroenterology. 2021 06; 160(7):2291-2302. Ma C, Sedano R, Almradi A, Vande Casteele N, Parker CE, Guizzetti L, Schaeffer DF, Riddell RH, Pai RK, Battat R, Sands BE, Rosty C, Dubinsky MC, Rieder F, Harpaz N, Abreu MT, Bryant RV, Lauwers GY, Kirsch R, Valasek MA, Crowley E, Sandborn WJ, Feagan BG, Pai RK, Jairath V. PMID: 33610533; PMCID: PMC8851891.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    135. Spatial Evolution of Histologic and Endoscopic Healing in the Left and Right Colon in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 04; 20(4):e750-e760. Jangi S, Holmer AK, Dulai PS, Boland B, Valasek M, Jairath V, Feagan BG, Sandborn WJ, Singh S. PMID: 33556578; PMCID: PMC9550577.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    136. Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis. Clin Pharmacol Drug Dev. 2021 03; 10(3):229-240. Vong C, Martin SW, Deng C, Xie R, Ito K, Su C, Sandborn WJ, Mukherjee A. PMID: 33513294; PMCID: PMC7986169.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    137. An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials. Aliment Pharmacol Ther. 2021 04; 53(7):784-793. Almradi A, Ma C, D'Haens GR, Sandborn WJ, Parker CE, Guizzetti L, Borralho Nunes P, De Hertogh G, Feakins RM, Khanna R, Lauwers GY, Mookhoek A, Pai RK, Peyrin-Biroulet L, Riddell R, Rosty C, Schaeffer DF, Valasek MA, Singh S, Crowley E, Feagan BG, Jairath V, Pai RK. PMID: 33410551.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    138. Routine incorporation of the local read in Crohn's disease clinical trials? Not so fast. Gastrointest Endosc. 2021 01; 93(1):183-186. Jairath V, Zou GY, Ma C, Feagan BG, Sandborn WJ. PMID: 33353616.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    139. A double-blind, 377-subject randomized study identifies Ruminococcus, Coprococcus, Christensenella, and Collinsella as long-term potential key players in the modulation of the gut microbiome of lactose intolerant individuals by galacto-oligosaccharides. Gut Microbes. 2021 Jan-Dec; 13(1):1957536. Azcarate-Peril MA, Roach J, Marsh A, Chey WD, Sandborn WJ, Ritter AJ, Savaiano DA, Klaenhammer TR. PMID: 34365905; PMCID: PMC8354614.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    140. Early Combined Immunosuppression Reduces Complications in Long-standing Crohn's Disease: A Post Hoc Analysis of REACT. Clin Gastroenterol Hepatol. 2022 01; 20(1):236-238. Hanzel J, Ma C, Zou G, Singh S, Dulai PS, Feagan BG, D'Haens GR, Sandborn WJ, Jairath V. PMID: 33346141.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    141. Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases. Aliment Pharmacol Ther. 2021 02; 53(3):374-382. Meserve J, Facciorusso A, Holmer AK, Annese V, Sandborn WJ, Singh S. PMID: 33314269; PMCID: PMC8041067.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    142. Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 02; 20(2):447-454.e1. Ma C, Jeyarajah J, Guizzetti L, Parker CE, Singh S, Dulai PS, D'Haens GR, Sandborn WJ, Feagan BG, Jairath V. PMID: 33279779; PMCID: PMC8588993.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    143. Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. Gastroenterology. 2021 03; 160(4):1131-1139. Mahadevan U, Long MD, Kane SV, Roy A, Dubinsky MC, Sands BE, Cohen RD, Chambers CD, Sandborn WJ, Crohn’s Colitis Foundation Clinical Research Alliance. PMID: 33227283; PMCID: PMC7956164.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    144. Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn's disease. Therap Adv Gastroenterol. 2020; 13:1756284820971214. Holmer AK, Battat R, Dulai PS, Vande Casteele N, Nguyen N, Jain A, Miralles A, Neill J, Le H, Singh S, Rivera-Nieves J, Sandborn WJ, Boland BS. PMID: 33240396; PMCID: PMC7675888.
      View in: PubMed   Mentions: 3  
    145. Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn's Disease: A Meta-Analysis of Population-Based Cohorts. Clin Gastroenterol Hepatol. 2021 10; 19(10):2031-2045.e11. Tsai L, Ma C, Dulai PS, Prokop LJ, Eisenstein S, Ramamoorthy SL, Feagan BG, Jairath V, Sandborn WJ, Singh S. PMID: 33127595; PMCID: PMC8934200.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    146. Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 08; 20(8):1821-1830.e3. Sandborn WJ, Peyrin-Biroulet L, Quirk D, Wang W, Nduaka CI, Mukherjee A, Su C, Sands BE. PMID: 33127596.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    147. Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. Aliment Pharmacol Ther. 2020 12; 52(11-12):1658-1675. Panaccione R, Danese S, Sandborn WJ, O'Brien CD, Zhou Y, Zhang H, Adedokun OJ, Tikhonov I, Targan S, Abreu MT, Hisamatsu T, Scherl EJ, Leong RW, Rowbotham DS, Arasaradnam RP, Sands BE, Marano C. PMID: 33086438; PMCID: PMC8776399.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    148. Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 01; 20(1):126-135. Lukin D, Faleck D, Xu R, Zhang Y, Weiss A, Aniwan S, Kadire S, Tran G, Rahal M, Winters A, Chablaney S, Koliani-Pace JL, Meserve J, Campbell JP, Kochhar G, Bohm M, Varma S, Fischer M, Boland B, Singh S, Hirten R, Ungaro R, Lasch K, Shmidt E, Jairath V, Hudesman D, Chang S, Swaminath A, Shen B, Kane S, Loftus EV, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS. PMID: 33039584; PMCID: PMC8026779.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    149. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. Lancet Gastroenterol Hepatol. 2020 12; 5(12):1063-1075. Atreya R, Peyrin-Biroulet L, Klymenko A, Augustyn M, Bakulin I, Slankamenac D, Miheller P, Gasbarrini A, Hébuterne X, Arnesson K, Knittel T, Kowalski J, Neurath MF, Sandborn WJ, Reinisch W, CONDUCT study group. PMID: 33031757.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    150. Evaluating the optimum number of biopsies to assess histological inflammation in ulcerative colitis: a retrospective cohort study. Aliment Pharmacol Ther. 2020 11; 52(10):1574-1582. Battat R, Vande Casteele N, Pai RK, Wang Z, Zou G, McDonald JWD, Duijvestein M, Jeyarajah J, Parker CE, Van Viegen T, Nelson SA, Boland BS, Singh S, Dulai PS, Valasek MA, Feagan BG, Jairath V, Sandborn WJ. PMID: 32981088; PMCID: PMC8007067.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    151. Defining Endpoints and Biomarkers in Inflammatory Bowel Disease: Moving the Needle Through Clinical Trial Design. Gastroenterology. 2020 12; 159(6):2013-2018.e7. Abreu MT, Sandborn WJ, IOIBD Defining Endpoints and Biomarkers in Inflammatory Bowel Disease Writing Group. PMID: 32961246.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    152. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2022 01; 20(1):105-115.e14. Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Hibi T, D'Haens GR, Tuttle JL, Krueger K, Friedrich S, Durante M, Arora V, Naegeli AN, Schmitz J, Feagan BG. PMID: 32950748.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    153. Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM Study. Inflamm Bowel Dis. 2020 09 18; 26(10):1562-1571. Reinisch W, Panaccione R, Bossuyt P, Baert F, Armuzzi A, Hébuterne X, Travis S, Danese S, Sandborn WJ, Schreiber S, Berg S, Zhou Q, Kligys K, Neimark E, Suleiman AA, D'Haens G, Colombel JF. PMID: 32105310; PMCID: PMC7500520.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    154. Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis. J Crohns Colitis. 2020 Sep 16; 14(9):1274-1281. Schreiber S, Hanauer SB, Sandborn WJ, Barrett K. PMID: 32179906.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    155. Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme. J Crohns Colitis. 2020 Sep 16; 14(9):1202-1213. Sandborn WJ, Nguyen DD, Beattie DT, Brassil P, Krey W, Woo J, Situ E, Sana R, Sandvik E, Pulido-Rios MT, Bhandari R, Leighton JA, Ganeshappa R, Boyle DL, Abhyankar B, Kleinschek MA, Graham RA, Panes J. PMID: 32161949; PMCID: PMC7493219.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansAnimalsCTClinical Trials
    156. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020 10; 52(8):1353-1365. Loftus EV, Feagan BG, Panaccione R, Colombel JF, Sandborn WJ, Sands BE, Danese S, D'Haens G, Rubin DT, Shafran I, Parfionovas A, Rogers R, Lirio RA, Vermeire S. PMID: 32876349; PMCID: PMC7540482.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    157. Understanding Determinants of Patient Preferences Between Stool Tests and Colonoscopy for the Assessment of Disease Activity in Inflammatory Bowel Disease. Dig Dis Sci. 2021 08; 66(8):2564-2569. Barsky M, Meserve J, Le H, Collins A, Singh S, Boland B, Sandborn WJ, Dulai PS. PMID: 32875527; PMCID: PMC7927417.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    158. Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis. Gastroenterology. 2020 12; 159(6):2052-2064. Li K, Marano C, Zhang H, Yang F, Sandborn WJ, Sands BE, Feagan BG, Rubin DT, Peyrin-Biroulet L, Friedman JR, De Hertogh G. PMID: 32853634.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    159. Heterogeneity and clonal relationships of adaptive immune cells in ulcerative colitis revealed by single-cell analyses. Sci Immunol. 2020 08 21; 5(50). Boland BS, He Z, Tsai MS, Olvera JG, Omilusik KD, Duong HG, Kim ES, Limary AE, Jin W, Milner JJ, Yu B, Patel SA, Louis TL, Tysl T, Kurd NS, Bortnick A, Quezada LK, Kanbar JN, Miralles A, Huylebroeck D, Valasek MA, Dulai PS, Singh S, Lu LF, Bui JD, Murre C, Sandborn WJ, Goldrath AW, Yeo GW, Chang JT. PMID: 32826341; PMCID: PMC7733868.
      View in: PubMed   Mentions: 98     Fields:    Translation:HumansAnimalsCells
    160. Short Disease Duration Is Associated With Increased Risk of Treatment Failure in Biologic-Treated Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2020 08 20; 26(9):1429-1435. Nguyen NH, Kurnool S, Dulai PS, Boland BS, Sandborn WJ, Singh S. PMID: 31748806; PMCID: PMC7441095.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    161. Frailty Is Independently Associated with Mortality and Readmission in Hospitalized Patients with Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2021 10; 19(10):2054-2063.e14. Qian AS, Nguyen NH, Elia J, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 32801013; PMCID: PMC7930013.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    162. Similar pharmacokinetics of three dosing regimens comprising two oral delayed-release mesalamine formulations in healthy adult volunteers: Randomised, open-label, parallel-group study. Br J Clin Pharmacol. 2021 03; 87(3):1141-1149. Vande Casteele N, Jakate A, McNamee B, Sandborn WJ. PMID: 32671846; PMCID: PMC9328660.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    163. Predictors and outcomes of histological remission in ulcerative colitis treated to endoscopic healing. Aliment Pharmacol Ther. 2020 09; 52(6):1008-1016. Jangi S, Yoon H, Dulai PS, Valasek M, Boland BS, Jairath V, Feagan BG, Sandborn WJ, Singh S. PMID: 33119168; PMCID: PMC8965793.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    164. A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis. Gastroenterology. 2021 01; 160(1):115-127.e30. Henn MR, O'Brien EJ, Diao L, Feagan BG, Sandborn WJ, Huttenhower C, Wortman JR, McGovern BH, Wang-Weigand S, Lichter DI, Chafee M, Ford CB, Bernardo P, Zhao P, Simmons S, Tomlinson AD, Cook DN, Pomerantz RJ, Misra BK, Auninš JG, Trucksis M. PMID: 32763240; PMCID: PMC7402096.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCellsCTClinical Trials
    165. Letter: combination of biologics in inflammatory bowel diseases. Authors' reply. Aliment Pharmacol Ther. 2020 08; 52(3):568-569. Yang E, Panaccione N, Whitmire N, Dulai PS, Vande Casteele N, Singh S, Boland BS, Collins A, Sandborn WJ, Panaccione R, Battat R. PMID: 32656846.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    166. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. Aliment Pharmacol Ther. 2020 08; 52(4):669-681. Bohm M, Xu R, Zhang Y, Varma S, Fischer M, Kochhar G, Boland B, Singh S, Hirten R, Ungaro R, Shmidt E, Lasch K, Jairaith V, Hudesman D, Chang S, Lukin D, Swaminath A, Sands BE, Colombel JF, Kane S, Loftus EV, Shen B, Siegel CA, Sandborn WJ, Dulai PS, VICTORY Collaboration. PMID: 32656800; PMCID: PMC7496810.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    167. No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy. Aliment Pharmacol Ther. 2020 08; 52(3):481-491. Singh S, Kim J, Zhu W, Dulai PS, Sandborn WJ, Jairath V. PMID: 32573825; PMCID: PMC8015755.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    168. Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis. Gastroenterology. 2020 10; 159(4):1262-1275.e7. Yoon H, Jangi S, Dulai PS, Boland BS, Prokop LJ, Jairath V, Feagan BG, Sandborn WJ, Singh S. PMID: 32585306; PMCID: PMC7658293.
      View in: PubMed   Mentions: 48     Fields:    Translation:Humans
    169. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study. Lancet Gastroenterol Hepatol. 2020 09; 5(9):819-828. Feagan BG, Sandborn WJ, Danese S, Wolf DC, Liu WJ, Hua SY, Minton N, Olson A, D'Haens G. PMID: 32553149.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCTClinical Trials
    170. Prevalence and Effects of Food Insecurity and Social Support on Financial Toxicity in and Healthcare Use by Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2021 07; 19(7):1377-1386.e5. Nguyen NH, Khera R, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 32526341; PMCID: PMC7987215.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    171. Letter: thromboembolic and cardiovascular events with tofacitinib in ulcerative colitis-two cases in real world clinical practice. Authors' reply. Aliment Pharmacol Ther. 2020 06; 51(11):1209-1210. Sandborn WJ, Panés J, Sands BE, Reinisch W, Su C, Lawendy N, Koram N, Fan H, Jones TV, Modesto I, Quirk D, Danese S. PMID: 32424928.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    172. Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. Am J Gastroenterol. 2020 06; 115(6):885-894. Dulai PS, Battat R, Barsky M, Nguyen NH, Ma C, Narula N, Mosli M, Vande Casteele N, Boland BS, Prokop L, Murad MH, D'Haens G, Feagan BG, Sandborn WJ, Jairath V, Singh S. PMID: 32384283; PMCID: PMC7274901.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    173. Etrolizumab for the Treatment of Ulcerative Colitis and Crohn's Disease: An Overview of the Phase 3 Clinical Program. Adv Ther. 2020 07; 37(7):3417-3431. Sandborn WJ, Vermeire S, Tyrrell H, Hassanali A, Lacey S, Tole S, Tatro AR, Etrolizumab Global Steering Committee. PMID: 32445184; PMCID: PMC7467434.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    174. Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021 06; 19(6):1170-1179.e10. Dulai PS, Sandborn WJ, Murphy J. PMID: 32437872.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    175. Development and Validation of a Clinical Decision Support Tool That Incorporates Pharmacokinetic Data to Predict Endoscopic Healing in Patients Treated With Infliximab. Clin Gastroenterol Hepatol. 2021 06; 19(6):1209-1217.e2. Vande Casteele N, Jairath V, Jeyarajah J, Dulai PS, Singh S, Shackelton LM, Feagan BG, Sandborn WJ. PMID: 32376505.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    176. Letter: corticosteroid use alongside tofacitinib in OCTAVE Open. Authors' reply. Aliment Pharmacol Ther. 2020 05; 51(10):997-998. Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B, Colombel JF, Lawendy N, Maller E, Zhang H, Chan G, Salese L, Tsilkos K, Marren A, Su C. PMID: 32338784.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    177. Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study. Am J Gastroenterol. 2020 05; 115(5):738-745. Sands BE, Feagan BG, Sandborn WJ, Schreiber S, Peyrin-Biroulet L, Frédéric Colombel J, Rossiter G, Usiskin K, Ather S, Zhan X, D'Haens G. PMID: 31850931.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCTClinical Trials
    178. Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol. 2021 03; 19(3):511-518.e6. Battat R, Hemperly A, Truong S, Whitmire N, Boland BS, Dulai PS, Holmer AK, Nguyen NH, Singh S, Vande Casteele N, Sandborn WJ. PMID: 32348905; PMCID: PMC7606215.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    179. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease. Aliment Pharmacol Ther. 2020 06; 51(11):1031-1038. Yang E, Panaccione N, Whitmire N, Dulai PS, Vande Casteele N, Singh S, Boland BS, Collins A, Sandborn WJ, Panaccione R, Battat R. PMID: 32329532; PMCID: PMC8032452.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    180. Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 2020 06; 51(11):1047-1066. Dulai PS, Jairath V, Khanna R, Ma C, McCarrier KP, Martin ML, Parker CE, Morris J, Feagan BG, Sandborn WJ. PMID: 32319120; PMCID: PMC7317756.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    181. Galacto-Oligosaccharide RP-G28 Improves Multiple Clinical Outcomes in Lactose-Intolerant Patients. Nutrients. 2020 Apr 10; 12(4). Chey W, Sandborn W, Ritter AJ, Foyt H, Azcarate-Peril MA, Savaiano DA. PMID: 32290344; PMCID: PMC7231374.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    182. Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis. Clin Transl Sci. 2020 07; 13(4):743-751. Paul S, Marotte H, Kavanaugh A, Goupille P, Kvien TK, de Longueville M, Mulleman D, Sandborn WJ, Vande Casteele N. PMID: 32100960; PMCID: PMC7359948.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    183. Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Arthritis Care Res (Hoboken). 2020 04; 72(4):561-576. Singh S, Fumery M, Singh AG, Singh N, Prokop LJ, Dulai PS, Sandborn WJ, Curtis JR. PMID: 30875456; PMCID: PMC6745288.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    184. Corticosteroid-Free Remission vs Overall Remission in Clinical Trials of Moderate-Severe Ulcerative Colitis and Crohn's Disease. Inflamm Bowel Dis. 2020 03 04; 26(4):515-523. George J, Singh S, Dulai PS, Ma C, Nguyen T, Feagan BG, Sandborn WJ, Jairath V. PMID: 31504528; PMCID: PMC8127062.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    185. Progression of Elderly Onset Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Population-Based Cohort Studies. Clin Gastroenterol Hepatol. 2020 10; 18(11):2437-2447.e6. Rozich JJ, Dulai PS, Fumery M, Sandborn WJ, Singh S. PMID: 32142940; PMCID: PMC7490750.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    186. Global chemical effects of the microbiome include new bile-acid conjugations. Nature. 2020 03; 579(7797):123-129. Quinn RA, Melnik AV, Vrbanac A, Fu T, Patras KA, Christy MP, Bodai Z, Belda-Ferre P, Tripathi A, Chung LK, Downes M, Welch RD, Quinn M, Humphrey G, Panitchpakdi M, Weldon KC, Aksenov A, da Silva R, Avila-Pacheco J, Clish C, Bae S, Mallick H, Franzosa EA, Lloyd-Price J, Bussell R, Thron T, Nelson AT, Wang M, Leszczynski E, Vargas F, Gauglitz JM, Meehan MJ, Gentry E, Arthur TD, Komor AC, Poulsen O, Boland BS, Chang JT, Sandborn WJ, Lim M, Garg N, Lumeng JC, Xavier RJ, Kazmierczak BI, Jain R, Egan M, Rhee KE, Ferguson D, Raffatellu M, Vlamakis H, Haddad GG, Siegel D, Huttenhower C, Mazmanian SK, Evans RM, Nizet V, Knight R, Dorrestein PC. PMID: 32103176; PMCID: PMC7252668.
      View in: PubMed   Mentions: 191     Fields:    Translation:HumansAnimals
    187. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis. Gastroenterology. 2020 06; 158(8):2139-2149.e14. Sandborn WJ, Ghosh S, Panes J, Schreiber S, D'Haens G, Tanida S, Siffledeen J, Enejosa J, Zhou W, Othman AA, Huang B, Higgins PDR. PMID: 32092309.
      View in: PubMed   Mentions: 93     Fields:    Translation:HumansCTClinical Trials
    188. Host engulfment pathway controls inflammation in inflammatory bowel disease. FEBS J. 2020 09; 287(18):3967-3988. Sayed IM, Suarez K, Lim E, Singh S, Pereira M, Ibeawuchi SR, Katkar G, Dunkel Y, Mittal Y, Chattopadhyay R, Guma M, Boland BS, Dulai PS, Sandborn WJ, Ghosh P, Das S. PMID: 32003126; PMCID: PMC7390677.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    189. Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 12; 18(13):2952-2961.e8. Dulai PS, Singh S, Vande Casteele N, Meserve J, Winters A, Chablaney S, Aniwan S, Shashi P, Kochhar G, Weiss A, Koliani-Pace JL, Gao Y, Boland BS, Chang JT, Faleck D, Hirten R, Ungaro R, Lukin D, Sultan K, Hudesman D, Chang S, Bohm M, Varma S, Fischer M, Shmidt E, Swaminath A, Gupta N, Rosario M, Jairath V, Guizzetti L, Feagan BG, Siegel CA, Shen B, Kane S, Loftus EV, Sandborn WJ, Sands BE, Colombel JF, Lasch K, Cao C. PMID: 32062041; PMCID: PMC7899124.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    190. Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. Gastroenterology. 2020 06; 158(8):2123-2138.e8. Sandborn WJ, Feagan BG, Loftus EV, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel JF, Lewis JD, Ghosh S, Armuzzi A, Scherl E, Herfarth H, Vitale L, Mohamed MF, Othman AA, Zhou Q, Huang B, Thakkar RB, Pangan AL, Lacerda AP, Panes J. PMID: 32044319.
      View in: PubMed   Mentions: 88     Fields:    Translation:HumansCTClinical Trials
    191. Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis. Clin Ther. 2020 01; 42(1):157-174.e4. Adedokun OJ, Xu Z, Liao S, Strauss R, Reinisch W, Feagan BG, Sandborn WJ. PMID: 31982148.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    192. Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group. Lancet Gastroenterol Hepatol. 2020 04; 5(4):393-405. Shen B, Kochhar G, Navaneethan U, Farraye FA, Schwartz DA, Iacucci M, Bernstein CN, Dryden G, Cross R, Bruining DH, Kobayashi T, Lukas M, Shergill A, Bortlik M, Lan N, Lukas M, Tang SJ, Kotze PG, Kiran RP, Dulai PS, El-Hachem S, Coelho-Prabhu N, Thakkar S, Mao R, Chen G, Zhang S, Suárez BG, Lama YG, Silverberg MS, Sandborn WJ. PMID: 31954438.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    193. First- and Second-Line Pharmacotherapies for Patients With Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis. Clin Gastroenterol Hepatol. 2020 09; 18(10):2179-2191.e6. Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. PMID: 31945470; PMCID: PMC8022894.
      View in: PubMed   Mentions: 104     Fields:    Translation:Humans
    194. Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. Inflamm Bowel Dis. 2020 01 06; 26(2):304-313. Lewis JD, Rutgeerts P, Feagan BG, D'haens G, Danese S, Colombel JF, Reinisch W, Rubin DT, Selinger C, Bewtra M, Barcomb L, Lacerda AP, Wallace K, Butler JW, Wu M, Zhou Q, Liao X, Sandborn WJ. PMID: 31644790.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    195. Current Endpoints of Clinical Trials in Ulcerative Colitis: Are They Valid? Curr Treat Options Gastroenterol. 2020 03; 18(1):15-32. Battat R, Dulai PS, Ma C, Jairath V, Feagan BG, Sandborn WJ, Khanna R. PMID: 31902071.
      View in: PubMed   Mentions:
    196. IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. J Crohns Colitis. 2020 Jan 01; 14(1):23-32. Hanauer SB, Sandborn WJ, Feagan BG, Gasink C, Jacobstein D, Zou B, Johanns J, Adedokun OJ, Sands BE, Rutgeerts P, de Villiers WJS, Colombel JF, Ghosh S. PMID: 31158271.
      View in: PubMed   Mentions: 73     Fields:    Translation:Humans
    197. A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. Aliment Pharmacol Ther. 2020 03; 51(5):553-564. Dulai PS, Amiot A, Peyrin-Biroulet L, Jairath V, Serrero M, Filippi J, Singh S, Pariente B, Loftus EV, Roblin X, Kane S, Buisson A, Siegel CA, Bouhnik Y, Sandborn WJ, Lasch K, Rosario M, Feagan BG, Bojic D, Trang-Poisson C, Shen B, Altwegg R, Sands BE, Colombel JF, Carbonnel F, GETAID OBSERV-IBD, VICTORY Cohorts Collaboration*. PMID: 31867766; PMCID: PMC7028036.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    198. Ustekinumab Pharmacokinetics and Exposure Response in a Phase 3 Randomized Trial of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 09; 18(10):2244-2255.e9. Adedokun OJ, Xu Z, Marano C, O'Brien C, Szapary P, Zhang H, Johanns J, Leong RW, Hisamatsu T, Van Assche G, Danese S, Abreu MT, Sands BE, Sandborn WJ. PMID: 31816446.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    199. Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. Aliment Pharmacol Ther. 2020 02; 51(4):435-445. Dulai PS, Singh S, Jairath V, Ma C, Narula N, Vande Casteele N, Peyrin-Biroulet L, Vermeire S, D'Haens G, Feagan BG, Sandborn WJ. PMID: 31755121; PMCID: PMC6989392.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    200. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020 02; 158(3):550-561. Sandborn WJ, Peyrin-Biroulet L, Zhang J, Chiorean M, Vermeire S, Lee SD, Kühbacher T, Yacyshyn B, Cabell CH, Naik SU, Klassen P, Panés J. PMID: 31711921.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansCTClinical Trials
    201. Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. Gastroenterology. 2020 02; 158(3):515-526.e10. D'Haens G, Kelly O, Battat R, Silverberg MS, Laharie D, Louis E, Savarino E, Bodini G, Yarur A, Boland BS, Afif W, Li XJ, Hale M, Ho J, Kondragunta V, Huang B, Kuy C, Okada L, Hester KD, Bray KR, Mimms L, Jain A, Singh S, Collins A, Valasek MA, Sandborn WJ, Vermeire S, Dulai PS. PMID: 31711925.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    202. Optimizing sequencing protocols for leaderboard metagenomics by combining long and short reads. Genome Biol. 2019 10 31; 20(1):226. Sanders JG, Nurk S, Salido RA, Minich J, Xu ZZ, Zhu Q, Martino C, Fedarko M, Arthur TD, Chen F, Boland BS, Humphrey GC, Brennan C, Sanders K, Gaffney J, Jepsen K, Khosroheidari M, Green C, Liyanage M, Dang JW, Phelan VV, Quinn RA, Bankevich A, Chang JT, Rana TM, Conrad DJ, Sandborn WJ, Smarr L, Dorrestein PC, Pevzner PA, Knight R. PMID: 31672156; PMCID: PMC6822431.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimals
    203. Positioning Therapies in the Management of Crohn's Disease. Clin Gastroenterol Hepatol. 2020 05; 18(6):1268-1279. Nguyen NH, Singh S, Sandborn WJ. PMID: 31676360; PMCID: PMC7183879.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    204. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Aliment Pharmacol Ther. 2020 01; 51(2):271-280. Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B, Colombel JF, Lawendy N, Maller E, Zhang H, Chan G, Salese L, Tsilkos K, Marren A, Su C. PMID: 31660640; PMCID: PMC9328429.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    205. Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. Inflamm Bowel Dis. 2019 10 18; 25(11):1854-1861. Koliani-Pace JL, Singh S, Luo M, Hirten R, Aniwan S, Kochhar G, Chang S, Lukin D, Gao Y, Bohm M, Swaminath A, Gupta N, Shmidt E, Meserve J, Winters A, Chablaney S, Faleck DM, Yang J, Huang Z, Boland BS, Shashi P, Weiss A, Hudesman D, Varma S, Fischer M, Sultan K, Shen B, Kane S, Loftus EV, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Siegel CA, Dulai PS. PMID: 31050734; PMCID: PMC6799947.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    206. Prevalence of Fistulizing Crohn's Disease in the United States: Estimate From a Systematic Literature Review Attempt and Population-Based Database Analysis. Inflamm Bowel Dis. 2019 10 18; 25(11):1773-1779. Schwartz DA, Tagarro I, Carmen Díez M, Sandborn WJ. PMID: 31216573; PMCID: PMC6799946.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    207. US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019 10 18; 25(11):1828-1837. Limketkai BN, Singh S, Jairath V, Sandborn WJ, Dulai PS. PMID: 31039246; PMCID: PMC6799945.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    208. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther. 2019 11; 50(10):1068-1076. Sandborn WJ, Panés J, Sands BE, Reinisch W, Su C, Lawendy N, Koram N, Fan H, Jones TV, Modesto I, Quirk D, Danese S. PMID: 31599001; PMCID: PMC6899755.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    209. Application of Artificial Intelligence to Gastroenterology and Hepatology. Gastroenterology. 2020 01; 158(1):76-94.e2. Le Berre C, Sandborn WJ, Aridhi S, Devignes MD, Fournier L, Smaïl-Tabbone M, Danese S, Peyrin-Biroulet L. PMID: 31593701.
      View in: PubMed   Mentions: 150     Fields:    Translation:Humans
    210. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2019 09 26; 381(13):1201-1214. Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C, UNIFI Study Group. PMID: 31553833.
      View in: PubMed   Mentions: 353     Fields:    Translation:HumansCTClinical Trials
    211. Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 07; 18(8):1760-1768.e1. Ma C, Sandborn WJ, D'Haens GR, Zou G, Stitt LW, Singh S, Ananthakrishnan AN, Dulai PS, Khanna R, Jairath V, Feagan BG. PMID: 31546056; PMCID: PMC7992966.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    212. Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials. J Crohns Colitis. 2019 Sep 19; 13(9):1227-1233. Hanauer S, Sandborn WJ, Colombel JF, Vermeire S, Petersson J, Kligys K, Zhou Q, Lazar A, Reinisch W. PMID: 30726897; PMCID: PMC6751337.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    213. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. Gastroenterology. 2020 02; 158(3):537-549.e10. Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Feagan BG, Hibi T, Tuttle JL, Klekotka P, Friedrich S, Durante M, Morgan-Cox M, Laskowski J, Schmitz J, D'Haens GR. PMID: 31493397.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCTClinical Trials
    214. Systematic review with meta-analysis: association between vedolizumab trough concentration and clinical outcomes in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2019 10; 50(8):848-857. Singh S, Dulai PS, Vande Casteele N, Battat R, Fumery M, Boland BS, Sandborn WJ. PMID: 31483522; PMCID: PMC7083298.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    215. Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn's Disease. Clin Gastroenterol Hepatol. 2020 08; 18(9):2139-2141.e2. Ma C, Gecse KB, Duijvestein M, Sandborn WJ, Zou G, Shackelton LM, Stitt LW, Parker CE, Bossuyt P, Löwenberg M, Khanna R, Vermeire S, Rutgeerts P, Feagan BG, Jairath V, D'Haens GR. PMID: 31473359.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    216. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020 02; 158(3):562-572.e12. Sandborn WJ, Baert F, Danese S, Krznaric Ž, Kobayashi T, Yao X, Chen J, Rosario M, Bhatia S, Kisfalvi K, D'Haens G, Vermeire S. PMID: 31470005.
      View in: PubMed   Mentions: 96     Fields:    Translation:HumansCTClinical Trials
    217. Rate of Risk Factors for and Interventions to Reduce Hospital Readmission in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2020 08; 18(9):1939-1948.e7. Nguyen NH, Koola J, Dulai PS, Prokop LJ, Sandborn WJ, Singh S. PMID: 31470176; PMCID: PMC7044053.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    218. Response to Placebo, Measured by Endoscopic Evaluation of Crohn's Disease Activity, in a Pooled Analysis of Data From 5 Randomized Controlled Induction Trials. Clin Gastroenterol Hepatol. 2020 05; 18(5):1121-1132.e2. Duijvestein M, Jeyarajah J, Guizzetti L, Zou G, Parker CE, van Viegen T, VandeCasteele N, Khanna R, Van Der Aa A, Sandborn WJ, Feagan BG, D'Haens GR, Jairath V. PMID: 31442599.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    219. Immunogenicity of Golimumab and its Clinical Relevance in Patients With Ulcerative Colitis. Inflamm Bowel Dis. 2019 08 20; 25(9):1532-1540. Adedokun OJ, Gunn GR, Leu JH, Gargano C, Xu Z, Sandborn WJ, Rutgeerts P, Shankar G. PMID: 30753466.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    220. Innovations in Oral Therapies for Inflammatory Bowel Disease. Drugs. 2019 Aug; 79(12):1321-1335. Ma C, Battat R, Dulai PS, Parker CE, Sandborn WJ, Feagan BG, Jairath V. PMID: 31317509.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    221. Development and Validation of a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn's Disease. Gastroenterology. 2019 11; 157(5):1233-1244.e5. Hindryckx P, Jairath V, Zou G, Feagan BG, Sandborn WJ, Stoker J, Khanna R, Stitt L, van Viegen T, Shackelton LM, Taylor SA, Santillan C, Mearadji B, D'Haens G, Richard MP, Panes J, Rimola J. PMID: 31336124.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    222. Effects of Ustekinumab on Histologic Disease Activity in Patients With Crohn's Disease. Gastroenterology. 2019 10; 157(4):1019-1031.e7. Li K, Friedman JR, Chan D, Pollack P, Yang F, Jacobstein D, Brodmerkel C, Gasink C, Feagan BG, Sandborn WJ, Rutgeerts P, De Hertogh G. PMID: 31279870.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    223. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn's Disease. Gastroenterology. 2019 10; 157(4):1007-1018.e7. Danese S, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, Siegelman J, Jones S, Bornstein JD, Feagan BG. PMID: 31279871.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCTClinical Trials
    224. Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. Gastroenterology. 2019 10; 157(4):1032-1043.e1. Dulai PS, Peyrin-Biroulet L, Danese S, Sands BE, Dignass A, Turner D, Mantzaris G, Schölmerich J, Mary JY, Reinisch W, Sandborn WJ. PMID: 31228441.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    225. Correction: Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials. Am J Gastroenterol. 2019 06; 114(6):1011. Singh S, Proudfoot J, Xu R, Sandborn WJ. PMID: 31033518.
      View in: PubMed   Mentions:    Fields:    
    226. Correction: No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. Am J Gastroenterol. 2019 06; 114(6):1010. Singh S, Proudfoot J, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ. PMID: 31033520.
      View in: PubMed   Mentions:    Fields:    
    227. Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn's disease: a pooled analysis of 11 317 patients across clinical trials. RMD Open. 2019; 5(1):e000942. Curtis JR, Mariette X, Gaujoux-Viala C, Blauvelt A, Kvien TK, Sandborn WJ, Winthrop K, de Longueville M, Huybrechts I, Bykerk VP. PMID: 31245056; PMCID: PMC6560674.
      View in: PubMed   Mentions: 30  Translation:Humans
    228. Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies. J Crohns Colitis. 2019 May 27; 13(6):725-734. Panaccione R, Löfberg R, Rutgeerts P, Sandborn WJ, Schreiber S, Berg S, Maa JF, Petersson J, Robinson AM, Colombel JF. PMID: 30753371; PMCID: PMC6535500.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    229. Comparative Efficacy and Speed of Onset of Action of Infliximab vs Golimumab in Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020 02; 18(2):424-431.e7. Singh S, Proudfoot JA, Dulai PS, Xu R, Feagan BG, Sandborn WJ, Jairath V. PMID: 31108227; PMCID: PMC6858937.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    230. Histologic Healing Rates of Medical Therapies for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Gastroenterol. 2019 05; 114(5):733-745. Battat R, Duijvestein M, Guizzetti L, Choudhary D, Boland BS, Dulai PS, Parker CE, Nguyen TM, Singh S, Vande Casteele N, Pai RK, Feagan BG, Sandborn WJ, Jairath V. PMID: 30694863.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    231. Should We Divide Crohn's Disease Into Ileum-Dominant and Isolated Colonic Diseases? Clin Gastroenterol Hepatol. 2019 12; 17(13):2634-2643. Dulai PS, Singh S, Vande Casteele N, Boland BS, Rivera-Nieves J, Ernst PB, Eckmann L, Barrett KE, Chang JT, Sandborn WJ. PMID: 31009791; PMCID: PMC6885453.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCells
    232. Evaluation of optimal biopsy location for assessment of histological activity, transcriptomic and immunohistochemical analyses in patients with active Crohn's disease. Aliment Pharmacol Ther. 2019 06; 49(11):1401-1409. Novak G, Stevens T, Van Viegen T, Bossuyt P, Štabuc B, Jeyarajah J, Zou G, Gaemers IC, McKee TD, Fu F, Shackelton LM, Khanna R, van den Brink GR, Sandborn WJ, Feagan BG, Pai RK, Jairath V, Vande Casteele N, D'Haens G. PMID: 30983024.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    233. Impact of Obesity on Disease Activity and Patient-Reported Outcomes Measurement Information System (PROMIS) in Inflammatory Bowel Diseases. Am J Gastroenterol. 2019 04; 114(4):630-639. Jain A, Nguyen NH, Proudfoot JA, Martin CF, Sandborn WJ, Kappelman MD, Long MD, Singh S. PMID: 30865012; PMCID: PMC6824268.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    234. Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies. Dig Dis Sci. 2019 09; 64(9):2478-2488. Dulai PS, Osterman MT, Lasch K, Cao C, Riaz F, Sandborn WJ. PMID: 30923985; PMCID: PMC6704097.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    235. Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT. Aliment Pharmacol Ther. 2019 05; 49(9):1188-1194. Singh S, Stitt LW, Zou G, Khanna R, Dulai PS, Sandborn WJ, Feagan BG, Jairath V. PMID: 30891808; PMCID: PMC6461484.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    236. Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists. Front Pharmacol. 2019; 10:212. Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Yarur A, Giles DA, Yeasmin S, Lundborg L, Sandborn WJ, Patel DR, Rivera-Nieves J. PMID: 30930775; PMCID: PMC6425155.
      View in: PubMed   Mentions: 39  
    237. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2020 01; 18(1):69-81.e3. Singh S, Facciorusso A, Dulai PS, Jairath V, Sandborn WJ. PMID: 30876964; PMCID: PMC8011651.
      View in: PubMed   Mentions: 71     Fields:    Translation:Humans
    238. Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis. J Crohns Colitis. 2019 Feb 01; 13(2):172-181. Sandborn WJ, Colombel JF, Panaccione R, Dulai PS, Rosario M, Cao C, Barocas M, Lasch K. PMID: 30285104; PMCID: PMC6357899.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    239. Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts. Inflamm Bowel Dis. 2019 01 10; 25(2):270-282. Pérez-Jeldres T, Tyler CJ, Boyer JD, Karuppuchamy T, Bamias G, Dulai PS, Boland BS, Sandborn WJ, Patel DR, Rivera-Nieves J. PMID: 30165490; PMCID: PMC6327230.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCells
    240. Biomarkers Are Associated With Clinical and Endoscopic Outcomes With Vedolizumab Treatment in Ulcerative Colitis. Inflamm Bowel Dis. 2019 01 10; 25(2):410-420. Battat R, Dulai PS, Vande Casteele N, Evans E, Hester KD, Webster E, Jain A, Proudfoot JA, Mairalles A, Neill J, Singh S, Chang JT, Rivera-Nieves J, Sandborn WJ, Boland BS. PMID: 30295781; PMCID: PMC6327228.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    241. Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 11; 17(12):2497-2505.e1. Faleck DM, Winters A, Chablaney S, Shashi P, Meserve J, Weiss A, Aniwan S, Koliani-Pace JL, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Kesar V, Lasch K, Luo M, Bohm M, Varma S, Fischer M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Shen B, Sandborn WJ, Kane S, Loftus EV, Sands BE, Colombel JF, Dulai PS, Ungaro R. PMID: 30625408; PMCID: PMC7026826.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    242. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. J Crohns Colitis. 2019 Jan 01; 13(1):50-57. Feagan BG, Sandborn WJ, Colombel JF, Byrne SO, Khalid JM, Kempf C, Geransar P, Bhayat F, Rubin DT. PMID: 30203005; PMCID: PMC6302953.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    243. Continuous Clinical Response Is Associated With a Change of Disease Course in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab. Inflamm Bowel Dis. 2019 01 01; 25(1):163-171. Reinisch W, Colombel JF, Gibson PR, Rutgeerts P, Sandborn WJ, Tarabar D, Huyck S, Khalifa A, Marano C, Philip G, Yao R, Zhang H, Cornillie F. PMID: 29982631.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    244. Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018 Dec; 113(12):696. Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS. PMID: 30390030; PMCID: PMC6455086.
      View in: PubMed   Mentions: 1     Fields:    
    245. Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 11 29; 24(12):2527-2542. Hemperly A, Sandborn WJ, Vande Casteele N. PMID: 29788338; PMCID: PMC11187819.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    246. Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis. Gastroenterology. 2019 03; 156(4):946-957.e18. Sandborn WJ, Cyrille M, Hansen MB, Feagan BG, Loftus EV, Rogler G, Vermeire S, Cruz ML, Yang J, Boedigheimer MJ, Abuqayyas L, Evangelista CM, Sullivan BA, Reinisch W. PMID: 30472236.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCells
    247. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clin Gastroenterol Hepatol. 2019 07; 17(8):1541-1550. Sandborn WJ, Panés J, D'Haens GR, Sands BE, Su C, Moscariello M, Jones T, Pedersen R, Friedman GS, Lawendy N, Chan G. PMID: 30476584.
      View in: PubMed   Mentions: 89     Fields:    Translation:HumansCTClinical Trials
    248. Serum Concentrations of 7α-hydroxy-4-cholesten-3-one Are Associated With Bile Acid Diarrhea in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2019 12; 17(13):2722-2730.e4. Battat R, Duijvestein M, Vande Casteele N, Singh S, Dulai PS, Valasek MA, Mimms L, McFarland J, Hester KD, Renshaw M, Jain A, Sandborn WJ, Boland BS. PMID: 30448597; PMCID: PMC6520204.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    249. Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study. J Crohns Colitis. 2018 Nov 09; 12(10):1158-1169. Sands BE, Sandborn WJ, Feagan BG, Lichtenstein GR, Zhang H, Strauss R, Szapary P, Johanns J, Panes J, Vermeire S, O'Brien CD, Yang Z, Bertelsen K, Marano C, Peficitinib-UC Study Group. PMID: 29917064.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    250. Metagenomics-Based, Strain-Level Analysis of Escherichia coli From a Time-Series of Microbiome Samples From a Crohn's Disease Patient. Front Microbiol. 2018; 9:2559. Fang X, Monk JM, Nurk S, Akseshina M, Zhu Q, Gemmell C, Gianetto-Hill C, Leung N, Szubin R, Sanders J, Beck PL, Li W, Sandborn WJ, Gray-Owen SD, Knight R, Allen-Vercoe E, Palsson BO, Smarr L. PMID: 30425690; PMCID: PMC6218438.
      View in: PubMed   Mentions: 30  
    251. Definitions of response and remission for the Robarts Histopathology Index. Gut. 2019 11; 68(11):2101-2102. Pai RK, Khanna R, D'Haens GR, Sandborn WJ, Jeyarajah J, Feagan BG, Vande Casteele N, Jairath V. PMID: 30366909.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    252. Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol. 2019 08; 17(9):1814-1821.e1. Vande Casteele N, Jeyarajah J, Jairath V, Feagan BG, Sandborn WJ. PMID: 30613004.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    253. Comparison of Multiplex Gastrointestinal Pathogen Panel and Conventional Stool Testing for Evaluation of Diarrhea in Patients with Inflammatory Bowel Diseases. Dig Dis Sci. 2019 02; 64(2):382-390. Ahmad W, Nguyen NH, Boland BS, Dulai PS, Pride DT, Bouland D, Sandborn WJ, Singh S. PMID: 30361807; PMCID: PMC6358459.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    254. Role of interventional inflammatory bowel disease in the era of biologic therapy: a position statement from the Global Interventional IBD Group. Gastrointest Endosc. 2019 02; 89(2):215-237. Shen B, Kochhar G, Navaneethan U, Liu X, Farraye FA, Gonzalez-Lama Y, Bruining D, Pardi DS, Lukas M, Bortlik M, Wu K, Sood A, Schwartz DA, Sandborn WJ, Global Interventional Inflammatory Bowel Disease Group. PMID: 30365985.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    255. A composite disease activity index for early drug development in ulcerative colitis: development and validation of the UC-100 score. Lancet Gastroenterol Hepatol. 2019 Jan; 4(1):63-70. Jairath V, Jeyarajah J, Zou G, Parker CE, Olson A, Khanna R, D'Haens GR, Sandborn WJ, Feagan BG. PMID: 30343116.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    256. Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 10 12; 24(11):2461-2467. Shmidt E, Kochhar G, Hartke J, Chilukuri P, Meserve J, Chaudrey K, Koliani-Pace JL, Hirten R, Faleck D, Barocas M, Luo M, Lasch K, Boland BS, Singh S, Vande Casteele N, Sagi SV, Fischer M, Chang S, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Kane S, Loftus EV, Sandborn WJ, Siegel CA, Sands BE, Colombel JF, Shen B, Dulai PS. PMID: 29788240; PMCID: PMC6693035.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    257. Implementation of Mass Cytometry as a Tool for Mechanism of Action Studies in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 10 12; 24(11):2366-2376. Tyler CJ, Pérez-Jeldres T, Ehinger E, Capaldo B, Karuppuchamy T, Boyer JD, Patel D, Dulai P, Boland BS, Lannigan J, Eckmann L, Ernst PB, Sandborn WJ, Ho SB, Rivera-Nieves J. PMID: 29889233; PMCID: PMC6185553.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    258. Obesity Is Independently Associated With Higher Annual Burden and Costs of Hospitalization in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 03; 17(4):709-718.e7. Nguyen NH, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 30012429.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    259. Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019 07; 17(8):1533-1540.e2. Meserve J, Aniwan S, Koliani-Pace JL, Shashi P, Weiss A, Faleck D, Winters A, Chablaney S, Kochhar G, Boland BS, Singh S, Hirten R, Shmidt E, Hartke JG, Chilukuri P, Bohm M, Sagi SV, Fischer M, Lukin D, Hudesman D, Chang S, Gao Y, Sultan K, Swaminath A, Gupta N, Kane S, Loftus EV, Shen B, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS. PMID: 30268561; PMCID: PMC6594363.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    260. Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis. Clin Gastroenterol Hepatol. 2019 07; 17(8):1525-1532.e1. Colombel JF, Adedokun OJ, Gasink C, Gao LL, Cornillie FJ, D'Haens GR, Rutgeerts PJ, Reinisch W, Sandborn WJ, Hanauer SB. PMID: 30267864.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    261. Microbiome 101: Studying, Analyzing, and Interpreting Gut Microbiome Data for Clinicians. Clin Gastroenterol Hepatol. 2019 01; 17(2):218-230. Allaband C, McDonald D, Vázquez-Baeza Y, Minich JJ, Tripathi A, Brenner DA, Loomba R, Smarr L, Sandborn WJ, Schnabl B, Dorrestein P, Zarrinpar A, Knight R. PMID: 30240894; PMCID: PMC6391518.
      View in: PubMed   Mentions: 112     Fields:    Translation:Humans
    262. Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Diseases: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials. Inflamm Bowel Dis. 2018 09 15; 24(10):2278-2284. Singh S, Proudfoot J, Xu R, Sandborn WJ. PMID: 29788260; PMCID: PMC6140448.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    263. Elevated A20 promotes TNF-induced and RIPK1-dependent intestinal epithelial cell death. Proc Natl Acad Sci U S A. 2018 09 25; 115(39):E9192-E9200. Garcia-Carbonell R, Wong J, Kim JY, Close LA, Boland BS, Wong TL, Harris PA, Ho SB, Das S, Ernst PB, Sasik R, Sandborn WJ, Bertin J, Gough PJ, Chang JT, Kelliher M, Boone D, Guma M, Karin M. PMID: 30209212; PMCID: PMC6166836.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansAnimalsCells
    264. Evolving Considerations for Thiopurine Therapy for Inflammatory Bowel Diseases-A Clinical Practice Update: Commentary. Gastroenterology. 2019 01; 156(1):36-42. Hanauer SB, Sandborn WJ, Lichtenstein GR. PMID: 30195449.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    265. Long-Term Benefit of Golimumab for Patients with Moderately to Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension. J Crohns Colitis. 2018 Aug 29; 12(9):1053-1066. Reinisch W, Gibson PR, Sandborn WJ, Feagan BG, Strauss R, Johanns J, Padgett L, Adedokun OJ, Colombel JF, Collins J, Rutgeerts P, Tarabar D, Marano C. PMID: 29917070.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    266. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease. Gastroenterology. 2018 10; 155(4):1045-1058. Rutgeerts P, Gasink C, Chan D, Lang Y, Pollack P, Colombel JF, Wolf DC, Jacobstein D, Johanns J, Szapary P, Adedokun OJ, Feagan BG, Sandborn WJ. PMID: 29909019.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCTClinical Trials
    267. Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease. J Crohns Colitis. 2018 Aug 29; 12(9):1021-1029. Sandborn WJ, Bhandari BR, Randall C, Younes ZH, Romanczyk T, Xin Y, Wendt E, Chai H, McKevitt M, Zhao S, Sundy JS, Keshav S, Danese S. PMID: 29767728; PMCID: PMC6113706.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    268. Project Sonar: A Community Practice-based Intensive Medical Home for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2018 12; 16(12):1847-1850.e1. Singh S, Brill JV, Proudfoot JA, Metcalfe L, Vu L, Sandborn WJ, Kosinski LR. PMID: 30149146.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    269. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Lancet Gastroenterol Hepatol. 2018 11; 3(11):742-753. Nguyen NH, Fumery M, Dulai PS, Prokop LJ, Sandborn WJ, Murad MH, Singh S. PMID: 30122356; PMCID: PMC6821871.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    270. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 08 16; 24(9):1876-1882. Dubinsky MC, Cross RK, Sandborn WJ, Long M, Song X, Shi N, Ding Y, Eichner S, Pappalardo B, Ganguli A, Wang A. PMID: 29668916.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    271. Responsiveness of histological disease activity indices in ulcerative colitis: a post hoc analysis using data from the TOUCHSTONE randomised controlled trial. Gut. 2019 07; 68(7):1162-1168. Jairath V, Peyrin-Biroulet L, Zou G, Mosli M, Vande Casteele N, Pai RK, Valasek MA, Marchal-Bressenot A, Stitt LW, Shackelton LM, Khanna R, D'Haens GR, Sandborn WJ, Olson A, Feagan BG, Pai RK. PMID: 30076171.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    272. Clinical Benefit of Long-Term Adalimumab Treatment in Patients With Crohn's Disease Following Loss of Response or Intolerance to Infliximab: 96-Week Efficacy Data From GAIN/ADHERE Trials. J Crohns Colitis. 2018 Jul 30; 12(8):930-938. Panaccione R, Sandborn WJ, D'Haens G, Wolf DC, Berg S, Maa JF, Petersson J, Robinson AM. PMID: 29697818; PMCID: PMC6065484.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    273. The Effects of Ustekinumab on Health-related Quality of Life in Patients With Moderate to Severe Crohn's Disease. J Crohns Colitis. 2018 Jul 30; 12(8):883-895. Sands BE, Han C, Gasink C, Jacobstein D, Szapary P, Gao LL, Lang Y, Targan S, Sandborn WJ, Feagan BG. PMID: 29726939.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    274. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study. Lancet Gastroenterol Hepatol. 2018 10; 3(10):671-680. Feagan BG, Panés J, Ferrante M, Kaser A, D'Haens GR, Sandborn WJ, Louis E, Neurath MF, Franchimont D, Dewit O, Seidler U, Kim KJ, Selinger C, Padula SJ, Herichova I, Robinson AM, Wallace K, Zhao J, Minocha M, Othman AA, Soaita A, Visvanathan S, Hall DB, Böcher WO. PMID: 30056030.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCTClinical Trials
    275. Pregnancy Outcomes Reported During the 13-Year TREAT Registry: A Descriptive Report. Am J Gastroenterol. 2018 11; 113(11):1678-1688. Lichtenstein GR, Feagan BG, Mahadevan U, Salzberg BA, Langholff W, Morgan JG, Safdi M, Nissinen R, Taillard F, Sandborn WJ, Cohen RD. PMID: 30022113.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansPHPublic Health
    276. Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis. Gastroenterology. 2018 10; 155(4):1008-1011.e8. Telesco SE, Brodmerkel C, Zhang H, Kim LL, Johanns J, Mazumder A, Li K, Baribaud F, Curran M, Strauss R, Paxson B, Plevy S, Davison T, Knight L, Dibben S, Schreiber S, Sandborn W, Rutgeerts P, Siegel CA, Reinisch W, Greenbaum LE. PMID: 29981298.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCellsCTClinical Trials
    277. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018 09; 113(9):1345. Narula N, Peerani F, Meserve J, Kochhar G, Chaudrey K, Hartke J, Chilukuri P, Koliani-Pace J, Winters A, Katta L, Shmidt E, Hirten R, Faleck D, Parikh MP, Whitehead D, Boland BS, Singh S, Sagi SV, Fischer M, Chang S, Barocas M, Luo M, Lasch K, Bohm M, Lukin D, Sultan K, Swaminath A, Hudesman D, Gupta N, Shen B, Kane S, Loftus EV, Siegel CA, Sands BE, Colombel JF, Sandborn WJ, Dulai PS. PMID: 29946178; PMCID: PMC6445254.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    278. No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. Am J Gastroenterol. 2018 08; 113(8):1197-1205. Singh S, Proudfoot JA, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ. PMID: 29925913; PMCID: PMC7107271.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    279. An expert consensus to standardise definitions, diagnosis and treatment targets for anti-fibrotic stricture therapies in Crohn's disease. Aliment Pharmacol Ther. 2018 08; 48(3):347-357. Rieder F, Bettenworth D, Ma C, Parker CE, Williamson LA, Nelson SA, van Assche G, Di Sabatino A, Bouhnik Y, Stidham RW, Dignass A, Rogler G, Taylor SA, Stoker J, Rimola J, Baker ME, Fletcher JG, Panes J, Sandborn WJ, Feagan BG, Jairath V. PMID: 29920726; PMCID: PMC6043370.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    280. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease. Aliment Pharmacol Ther. 2018 08; 48(4):394-409. Singh S, Fumery M, Sandborn WJ, Murad MH. PMID: 29920733.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    281. Obesity and Response to Infliximab in Patients with Inflammatory Bowel Diseases: Pooled Analysis of Individual Participant Data from Clinical Trials. Am J Gastroenterol. 2018 06; 113(6):883-889. Singh S, Proudfoot J, Xu R, Sandborn WJ. PMID: 29867171; PMCID: PMC7107273.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    282. Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. Gastroenterology. 2018 09; 155(3):687-695.e10. Dulai PS, Boland BS, Singh S, Chaudrey K, Koliani-Pace JL, Kochhar G, Parikh MP, Shmidt E, Hartke J, Chilukuri P, Meserve J, Whitehead D, Hirten R, Winters AC, Katta LG, Peerani F, Narula N, Sultan K, Swaminath A, Bohm M, Lukin D, Hudesman D, Chang JT, Rivera-Nieves J, Jairath V, Zou GY, Feagan BG, Shen B, Siegel CA, Loftus EV, Kane S, Sands BE, Colombel JF, Sandborn WJ, Lasch K, Cao C. PMID: 29857091; PMCID: PMC6419724.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    283. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. J Crohns Colitis. 2018 May 25; 12(6):635-643. Singh S, George J, Boland BS, Vande Casteele N, Sandborn WJ. PMID: 29370397; PMCID: PMC7189966.
      View in: PubMed   Mentions: 82     Fields:    Translation:Humans
    284. Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Ther. 2018 07; 48(1):65-77. Sandborn WJ, Rutgeerts P, Gasink C, Jacobstein D, Zou B, Johanns J, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJS, Colombel JF, Feagan BG. PMID: 29797519; PMCID: PMC6032827.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCTClinical Trials
    285. Efficacy and Safety of Endoscopic Balloon Dilatation of Ileoanal Pouch Strictures. Inflamm Bowel Dis. 2018 05 18; 24(6):1316-1320. Fumery M, Patel NS, Boland BS, Dulai PS, Singh S, Sandborn WJ. PMID: 29697797; PMCID: PMC6231369.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    286. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis. PLoS One. 2018; 13(5):e0195123. Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, Prokop LJ, Grunvald EL, Curtis JR, Sandborn WJ. PMID: 29771924; PMCID: PMC5957395.
      View in: PubMed   Mentions: 106     Fields:    Translation:Humans
    287. A Noninvasive Method to Assess Mucosal Healing in Patients* With Crohn's Disease. Gastroenterol Hepatol (N Y). 2018 May; 14(5 Suppl 2):1-12. Sandborn WJ, Abreu MT, Dubinsky MC. PMID: 29991933; PMCID: PMC6018319.
      View in: PubMed   Mentions: 5  
    288. Corrigendum: Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. J Crohns Colitis. 2018 04 27; 12(5):631. Jairath V, Levesque BG, Vande Casteele N, Khanna R, Mosli M, Hindryckx P, Travis S, Duijvestein M, Rimola J, Panes J, D'Haens G, Sandborn WJ, Feagan BG. PMID: 29566131.
      View in: PubMed   Mentions:    Fields:    
    289. Systematic review with meta-analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis. Aliment Pharmacol Ther. 2018 06; 47(12):1578-1596. Ma C, Guizzetti L, Panaccione R, Fedorak RN, Pai RK, Parker CE, Nguyen TM, Khanna R, Vande Casteele N, D'Haens G, Sandborn WJ, Feagan BG, Jairath V. PMID: 29696670.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    290. Performance of Crohn's disease Clinical Trial Endpoints based upon Different Cutoffs for Patient Reported Outcomes or Endoscopic Activity: Analysis of EXTEND Data. Inflamm Bowel Dis. 2018 04 23; 24(5):932-942. Feagan B, Sandborn WJ, Rutgeerts P, Levesque BG, Khanna R, Huang B, Zhou Q, Maa JF, Wallace K, Lacerda A, Thakkar RB, Robinson AM. PMID: 29668919.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    291. High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis. Aliment Pharmacol Ther. 2018 06; 47(11):1472-1479. Kurnool S, Nguyen NH, Proudfoot J, Dulai PS, Boland BS, Vande Casteele N, Evans E, Grunvald EL, Zarrinpar A, Sandborn WJ, Singh S. PMID: 29665045; PMCID: PMC5992082.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    292. Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. Gastrointest Endosc. 2018 08; 88(2):360-369.e2. Samaan MA, Shen B, Mosli MH, Zou G, Sandborn WJ, Shackelton LM, Nelson S, Stitt L, Bloom S, Pardi DS, Gionchetti P, Lindsay J, Travis S, Hart A, Silverberg MS, Feagan BG, D'Haens GR, Jairath V. PMID: 29660321.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    293. Ustekinumab IV 6 mg/kg Loading Dose Re-induction Improves Clinical and Endoscopic Response in Crohn's disease: A Case Series. Am J Gastroenterol. 2018 04; 113(4):627-629. Park S, Evans E, Sandborn WJ, Boland B. PMID: 29610516.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    294. Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. Gastroenterology. 2018 07; 155(1):76-87. Danese S, Bonovas S, Lopez A, Fiorino G, Sandborn WJ, Rubin DT, Kamm MA, Colombel JF, Sands BE, Vermeire S, Panes J, Rogler G, D'Haens G, Peyrin-Biroulet L. PMID: 29601825.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    295. Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. J Crohns Colitis. 2018 03 28; 12(4):510. Rosario M, French JL, Dirks NL, Sankoh S, Parikh A, Yang H, Danese S, Colombel JF, Smyth M, Sandborn WJ, Feagan BG, Reinisch W, Sands BE, Sans M, Fox I. PMID: 29385425.
      View in: PubMed   Mentions: 1     Fields:    
    296. Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn's Disease: A Systematic Review. Clin Gastroenterol Hepatol. 2018 09; 16(9):1407-1419.e22. Ma C, Hussein IM, Al-Abbar YJ, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-Biroulet L, Pai RK, Vande Casteele N, D'Haens GR, Sandborn WJ, Feagan BG, Jairath V. PMID: 29596987.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    297. Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study. Inflamm Bowel Dis. 2018 03 19; 24(4):871-876. Lightner AL, Mathis KL, Tse CS, Pemberton JH, Shen B, Kochhar G, Singh A, Dulai PS, Eisenstein S, Sandborn WJ, Parry L, Stringfield S, Hudesman D, Remzi F, Loftus EV. PMID: 29509927.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    298. Infections and Cardiovascular Complications are Common Causes for Hospitalization in Older Patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2018 03 19; 24(4):916-923. Nguyen NH, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 29562273.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    299. Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease. Curr Treat Options Gastroenterol. 2018 Mar; 16(1):129-146. Duijvestein M, Battat R, Vande Casteele N, D'Haens GR, Sandborn WJ, Khanna R, Jairath V, Feagan BG. PMID: 29411220.
      View in: PubMed   Mentions: 33  
    300. Annual Burden and Costs of Hospitalization for High-Need, High-Cost Patients With Chronic Gastrointestinal and Liver Diseases. Clin Gastroenterol Hepatol. 2018 08; 16(8):1284-1292.e30. Nguyen NH, Khera R, Ohno-Machado L, Sandborn WJ, Singh S. PMID: 29474966; PMCID: PMC6056327.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    301. Reliability of histologic assessment in patients with eosinophilic oesophagitis. Aliment Pharmacol Ther. 2018 Apr; 47(7):940-950. Warners MJ, Ambarus CA, Bredenoord AJ, Verheij J, Lauwers GY, Walsh JC, Katzka DA, Nelson S, van Viegen T, Furuta GT, Gupta SK, Stitt L, Zou G, Parker CE, Shackelton LM, D Haens GR, Sandborn WJ, Dellon ES, Feagan BG, Collins MH, Jairath V, Pai RK. PMID: 29460418.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    302. Infliximab for Crohn's Disease: More Than 13 Years of Real-world Experience. Inflamm Bowel Dis. 2018 02 15; 24(3):490-501. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Safdi M, Popp JW, Langholff W, Sandborn WJ. PMID: 29462395; PMCID: PMC6176880.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    303. Tracking Human Gut Microbiome Changes Resulting from a Colonoscopy. Methods Inf Med. 2017; 56(6):442-447. Smarr L, Hyde ER, McDonald D, Sandborn WJ, Knight R. PMID: 29582916.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    304. Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's Disease. Gastroenterology. 2018 05; 154(6):1660-1671. Adedokun OJ, Xu Z, Gasink C, Jacobstein D, Szapary P, Johanns J, Gao LL, Davis HM, Hanauer SB, Feagan BG, Ghosh S, Sandborn WJ. PMID: 29409871.
      View in: PubMed   Mentions: 81     Fields:    Translation:Humans
    305. Development of Clinical Prediction Models for Surgery and Complications in Crohn's Disease. J Crohns Colitis. 2018 Jan 24; 12(2):167-177. Guizzetti L, Zou G, Khanna R, Dulai PS, Sandborn WJ, Jairath V, Feagan BG. PMID: 29028958; PMCID: PMC5881746.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    306. Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study. J Crohns Colitis. 2018 Jan 24; 12(2):188-196. D'Haens G, Vermeire S, Vogelsang H, Allez M, Desreumaux P, Van Gossum A, Sandborn WJ, Baumgart DC, Ransohoff RM, Comer GM, Ahmad A, Cataldi F, Cheng J, Clare R, Gorelick KJ, Kaminski A, Pradhan V, Rivers S, Sikpi MO, Zhang Y, Hassan-Zahraee M, Reinisch W, Stuve O. PMID: 28961770; PMCID: PMC5881743.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    307. Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey. Aliment Pharmacol Ther. 2018 Mar; 47(6):773-783. Olivera P, Sandborn WJ, Panés J, Baumann C, D'Haens G, Vermeire S, Danese S, Peyrin-Biroulet L. PMID: 29349829.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    308. Genetic risk, dysbiosis, and treatment stratification using host genome and gut microbiome in inflammatory bowel disease. Clin Transl Gastroenterol. 2018 Jan 18; 9(1):e132. Moustafa A, Li W, Anderson EL, Wong EHM, Dulai PS, Sandborn WJ, Biggs W, Yooseph S, Jones MB, Venter JC, Nelson KE, Chang JT, Telenti A, Boland BS. PMID: 29345635; PMCID: PMC5795019.
      View in: PubMed   Mentions: 49     Fields:    
    309. Biomarker-Based Models Outperform Patient-Reported Scores in Predicting Endoscopic Inflammatory Disease Activity. Inflamm Bowel Dis. 2018 01 18; 24(2):277-285. Morris MW, Stewart SA, Heisler C, Sandborn WJ, Loftus EV, Zello GA, Fowler SA, Jones JL. PMID: 29361090.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    310. Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance Enterography. Inflamm Bowel Dis. 2018 01 18; 24(2):440-449. Jairath V, Ordas I, Zou G, Panes J, Stoker J, Taylor SA, Santillan C, Horsthuis K, Samaan MA, Shackelton LM, Stitt LW, Hindryckx P, Khanna R, Sandborn WJ, D'Haens G, Feagan BG, Levesque BG, Rimola J. PMID: 29361096.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    311. Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn's Disease. Radiology. 2018 Mar; 286(3):776-799. Bruining DH, Zimmermann EM, Loftus EV, Sandborn WJ, Sauer CG, Strong SA, Society of Abdominal Radiology Crohn’s Disease-Focused Panel. PMID: 29319414.
      View in: PubMed   Mentions: 86     Fields:    Translation:Humans
    312. Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn's Disease. Gastroenterology. 2018 Mar; 154(4):1172-1194. Bruining DH, Zimmermann EM, Loftus EV, Sandborn WJ, Sauer CG, Strong SA, Society of Abdominal Radiology Crohn’s Disease-Focused Panel. PMID: 29329905.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    313. The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients? J Crohns Colitis. 2018 Jan 05; 12(1):105-119. Hindryckx P, Vande Casteele N, Novak G, Khanna R, D'Haens G, Sandborn WJ, Danese S, Jairath V, Feagan BG. PMID: 28961959.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    314. Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 12 04; 11(12):1510. Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP. PMID: 28453665; PMCID: PMC5951008.
      View in: PubMed   Mentions:    Fields:    
    315. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 2018 01; 47(2):162-175. Singh S, Fumery M, Sandborn WJ, Murad MH. PMID: 29205406.
      View in: PubMed   Mentions: 79     Fields:    Translation:Humans
    316. Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease. Clin Pharmacokinet. 2017 12; 56(12):1513-1523. Vande Casteele N, Mould DR, Coarse J, Hasan I, Gils A, Feagan B, Sandborn WJ. PMID: 28353055.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    317. Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease. Aliment Pharmacol Ther. 2018 01; 47(2):229-237. Vande Casteele N, Feagan BG, Vermeire S, Yassine M, Coarse J, Kosutic G, Sandborn WJ. PMID: 29159893; PMCID: PMC5765392.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    318. Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. Aliment Pharmacol Ther. 2018 01; 47(2):219-228. Colombel JF, Sandborn WJ, Reinisch W, Peyrin-Biroulet L, Panaccione R, Rutgeerts P, Hanauer SB, Ghosh S, Van Assche G, Robinson AM, Lau W, Maa JF, Huang B, Pappalardo B, Read H. PMID: 29159817.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    319. Population Health Management for Inflammatory Bowel Disease. Gastroenterology. 2018 01; 154(1):37-45. Dulai PS, Singh S, Ohno-Machado L, Sandborn WJ. PMID: 29122544.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    320. Centrally Determined Standardization of Flow Cytometry Methods Reduces Interlaboratory Variation in a Prospective Multicenter Study. Clin Transl Gastroenterol. 2017 Nov 02; 8(11):e126. Westera L, van Viegen T, Jeyarajah J, Azad A, Bilsborough J, van den Brink GR, Cremer J, Danese S, D'Haens G, Eckmann L, Faubion W, Filice M, Korf H, McGovern D, Panes J, Salas A, Sandborn WJ, Silverberg MS, Smith MI, Vermeire S, Vetrano S, Shackelton LM, Stitt L, Jairath V, Levesque BG, Spencer DM, Feagan BG, Vande Casteele N. PMID: 29095427; PMCID: PMC5717516.
      View in: PubMed   Mentions: 4     Fields:    
    321. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017 12 23; 390(10114):2779-2789. Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vanásek T, Danalioglu A, Novacek G, Armuzzi A, Hébuterne X, Travis S, Danese S, Reinisch W, Sandborn WJ, Rutgeerts P, Hommes D, Schreiber S, Neimark E, Huang B, Zhou Q, Mendez P, Petersson J, Wallace K, Robinson AM, Thakkar RB, D'Haens G. PMID: 29096949.
      View in: PubMed   Mentions: 269     Fields:    Translation:HumansCTClinical Trials
    322. Systematic Review: Disease Activity Indices in Eosinophilic Esophagitis. Am J Gastroenterol. 2017 Nov; 112(11):1658-1669. Warners MJ, Hindryckx P, Levesque BG, Parker CE, Shackelton LM, Khanna R, Sandborn WJ, D'Haens GR, Feagan BG, Bredenoord AJ, Jairath V. PMID: 29039850.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    323. Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study. Gut. 2018 10; 67(10):1824-1835. Sandborn WJ, Lee SD, Tarabar D, Louis E, Klopocka M, Klaus J, Reinisch W, Hébuterne X, Park DI, Schreiber S, Nayak S, Ahmad A, Banerjee A, Brown LS, Cataldi F, Gorelick KJ, Cheng JB, Hassan-Zahraee M, Clare R, D'Haens GR. PMID: 28982740; PMCID: PMC6145284.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    324. Endoscopy in inflammatory bowel disease: advances in dysplasia detection and management. Gastrointest Endosc. 2017 12; 86(6):962-971. Kaltenbach T, Sandborn WJ. PMID: 28987547.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    325. Vedolizumab in Patients With Common Variable Immune Deficiency and Gut Inflammation. Am J Gastroenterol. 2017 10; 112(10):1621. Boland BS, Riedl MA, Valasek MA, Crowe SE, Sandborn WJ. PMID: 28978958; PMCID: PMC6389596.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    326. Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis. Cochrane Database Syst Rev. 2017 09 08; 9:CD011572. Jairath V, Zou GY, Parker CE, MacDonald JK, AlAmeel T, Al Beshir M, Almadi MA, Al-Taweel T, Atkinson NS, Biswas S, Chapman T, Dulai PS, Glaire MA, Hoekman DR, Koutsoumpas A, Minas E, Mosli MH, Samaan M, Khanna R, Travis S, D'Haens G, Sandborn WJ, Feagan BG. PMID: 28886205; PMCID: PMC6483671.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    327. Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease. Gastroenterol Clin North Am. 2017 09; 46(3):603-626. Deepak P, Sandborn WJ. PMID: 28838418.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    328. Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clin Gastroenterol Hepatol. 2018 05; 16(5):637-647.e13. Ma C, Panaccione R, Fedorak RN, Parker CE, Nguyen TM, Khanna R, Siegel CA, Peyrin-Biroulet L, D'Haens G, Sandborn WJ, Feagan BG, Jairath V. PMID: 28843356.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    329. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017 08 03; 377(5):496-7. Sandborn WJ, Su C, Panes J. PMID: 28767341.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    330. Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease. J Crohns Colitis. 2017 Aug 01; 11(8):921-929. Rosario M, French JL, Dirks NL, Sankoh S, Parikh A, Yang H, Danese S, Colombel JF, Smyth M, Sandborn WJ, Feagan BG, Reinisch W, Sands BE, Sans M, Fox I. PMID: 28333288.
      View in: PubMed   Mentions: 67     Fields:    Translation:Humans
    331. Histologic scoring indices for evaluation of disease activity in Crohn's disease. Cochrane Database Syst Rev. 2017 Jul 21; 7:CD012351. Novak G, Parker CE, Pai RK, MacDonald JK, Feagan BG, Sandborn WJ, D'Haens G, Jairath V, Khanna R. PMID: 28731502; PMCID: PMC6483549.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    332. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. J Crohns Colitis. 2017 Jul 01; 11(7):785-791. Rubin DT, Cohen RD, Sandborn WJ, Lichtenstein GR, Axler J, Riddell RH, Zhu C, Barrett AC, Bortey E, Forbes WP. PMID: 28333362; PMCID: PMC5881669.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    333. Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease. Inflamm Bowel Dis. 2017 07; 23(7):1047-1056. Sandborn WJ, Wolf DC, Kosutic G, Parker G, Schreiber S, Lee SD, Abraham B, Afzali A, Arsenescu RI, Gutierrez A, Spearman M, Coarse J, Feagan BG. PMID: 28410341.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    334. Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study. J Crohns Colitis. 2017 Jul 01; 11(7):811-819. Sandborn WJ, Rutgeerts P, Colombel JF, Ghosh S, Petryka R, Sands BE, Mitra P, Luo A. PMID: 28333187.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    335. The development of a magnetic resonance imaging index for fistulising Crohn's disease. Aliment Pharmacol Ther. 2017 09; 46(5):516-528. Samaan MA, Puylaert CAJ, Levesque BG, Zou GY, Stitt L, Taylor SA, Shackelton LM, Vandervoort MK, Khanna R, Santillan C, Rimola J, Hindryckx P, Nio CY, Sandborn WJ, D'Haens G, Feagan BG, Jairath V, Stoker J. PMID: 28653753.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    336. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clin Gastroenterol Hepatol. 2018 03; 16(3):343-356.e3. Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ. PMID: 28625817; PMCID: PMC6658168.
      View in: PubMed   Mentions: 140     Fields:    Translation:Humans
    337. Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. BMJ Open. 2017 06 09; 7(6):e016146. Ma C, Panaccione R, Fedorak RN, Parker CE, Khanna R, Levesque BG, Sandborn WJ, Feagan BG, Jairath V. PMID: 28601837; PMCID: PMC5726090.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    338. Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis. Aliment Pharmacol Ther. 2017 08; 46(3):292-302. D'Haens GR, Sandborn WJ, Zou G, Stitt LW, Rutgeerts PJ, Gilgen D, Jairath V, Hindryckx P, Shackelton LM, Vandervoort MK, Parker CE, Muller C, Pai RK, Levchenko O, Marakhouski Y, Horynski M, Mikhailova E, Kharchenko N, Pimanov S, Feagan BG. PMID: 28568974.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    339. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2017 07 08; 390(10090):135-144. Vermeire S, Sandborn WJ, Danese S, Hébuterne X, Salzberg BA, Klopocka M, Tarabar D, Vanasek T, Greguš M, Hellstern PA, Kim JS, Sparrow MP, Gorelick KJ, Hinz M, Ahmad A, Pradhan V, Hassan-Zahraee M, Clare R, Cataldi F, Reinisch W. PMID: 28527704.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCTClinical Trials
    340. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017 05 04; 376(18):1723-1736. Sandborn WJ, Su C, Sands BE, D'Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G, Lawendy N, Yu D, Woodworth D, Mukherjee A, Zhang H, Healey P, Panés J, OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. PMID: 28467869.
      View in: PubMed   Mentions: 513     Fields:    Translation:HumansCTClinical Trials
    341. Corrigendum: Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease. Am J Gastroenterol. 2017 06; 112(6):975. Khanna R, Zou G, Stitt L, Feagan BG, Sandborn WJ, Rutgeerts P, McDonald JWD, Dubcenco E, Fogel R, Panaccione R, Jairath V, Nelson S, Shackelton LM, Huang B, Zhou Q, Robinson AM, Levesque BG, D'Haens G. PMID: 28417993.
      View in: PubMed   Mentions: 2     Fields:    
    342. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017 04 29; 389(10080):1699-1709. Feagan BG, Sandborn WJ, D'Haens G, Panés J, Kaser A, Ferrante M, Louis E, Franchimont D, Dewit O, Seidler U, Kim KJ, Neurath MF, Schreiber S, Scholl P, Pamulapati C, Lalovic B, Visvanathan S, Padula SJ, Herichova I, Soaita A, Hall DB, Böcher WO. PMID: 28411872.
      View in: PubMed   Mentions: 178     Fields:    Translation:HumansCTClinical Trials
    343. Characterisation of Mucosal Healing with Adalimumab Treatment in Patients with Moderately to Severely Active Crohn's Disease: Results from the EXTEND Trial. J Crohns Colitis. 2017 Apr 01; 11(4):425-434. Reinisch W, Colombel JF, D'Haens G, Sandborn WJ, Rutgeerts P, Geboes K, Petersson J, Eichner S, Zhou Q, Robinson AM, Read HA, Thakkar R. PMID: 27815351; PMCID: PMC5881717.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    344. Long-term Efficacy of Vedolizumab for Crohn's Disease. J Crohns Colitis. 2017 Apr 01; 11(4):412-424. Vermeire S, Loftus EV, Colombel JF, Feagan BG, Sandborn WJ, Sands BE, Danese S, D'Haens GR, Kaser A, Panaccione R, Rubin DT, Shafran I, McAuliffe M, Kaviya A, Sankoh S, Mody R, Abhyankar B, Smyth M. PMID: 27683798.
      View in: PubMed   Mentions: 84     Fields:    Translation:Humans
    345. Long-term Efficacy of Vedolizumab for Ulcerative Colitis. J Crohns Colitis. 2017 Apr 01; 11(4):400-411. Loftus EV, Colombel JF, Feagan BG, Vermeire S, Sandborn WJ, Sands BE, Danese S, D'Haens GR, Kaser A, Panaccione R, Rubin DT, Shafran I, McAuliffe M, Kaviya A, Sankoh S, Mody R, Abhyankar B, Smyth M. PMID: 27683800.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCTClinical Trials
    346. Head-to-head Comparative Studies: Challenges and Opportunities? J Crohns Colitis. 2017 Mar 01; 11(suppl_2):S567-S575. Peyrin-Biroulet L, Lopez A, Sandborn W. PMID: 27660343.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    347. Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. Aliment Pharmacol Ther. 2017 04; 45(8):1058-1072. Allen PB, Olivera P, Emery P, Moulin D, Jouzeau JY, Netter P, Danese S, Feagan B, Sandborn WJ, Peyrin-Biroulet L. PMID: 28247573.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    348. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017 06; 66(6):1049-1059. Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E. PMID: 28209624; PMCID: PMC5532457.
      View in: PubMed   Mentions: 129     Fields:    Translation:HumansCTClinical Trials
    349. Systematic review with meta-analysis: placebo rates in induction and maintenance trials of Crohn's disease. Aliment Pharmacol Ther. 2017 04; 45(8):1021-1042. Jairath V, Zou G, Parker CE, MacDonald JK, Mosli MH, AlAmeel T, Al Beshir M, AlMadi M, Al-Taweel T, Atkinson NS, Biswas S, Chapman TP, Dulai PS, Glaire MA, Hoekman D, Kherad O, Koutsoumpas A, Minas E, Restellini S, Samaan MA, Khanna R, Levesque BG, D'Haens G, Sandborn WJ, Feagan BG. PMID: 28164348.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    350. Review article: dose optimisation of infliximab for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2017 03; 45(5):617-630. Hindryckx P, Novak G, Vande Casteele N, Laukens D, Parker C, Shackelton LM, Narula N, Khanna R, Dulai P, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG, Jairath V. PMID: 28074618; PMCID: PMC6658182.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    351. Responsiveness of Endoscopic Indices of Disease Activity for Crohn's Disease. Am J Gastroenterol. 2017 Oct; 112(10):1584-1592. Khanna R, Zou G, Stitt L, Feagan BG, Sandborn WJ, Rutgeerts P, McDonald JWD, Dubcenco E, Fogel R, Panaccione R, Jairath V, Nelson S, Shackelton LM, Huang B, Zhou Q, Robinson AM, Levesque BG, D'Haens G. PMID: 28071654.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    352. Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy. Inflamm Bowel Dis. 2017 01; 23(1):97-106. Sands BE, Sandborn WJ, Van Assche G, Lukas M, Xu J, James A, Abhyankar B, Lasch K. PMID: 27930408.
      View in: PubMed   Mentions: 79     Fields:    Translation:HumansCTClinical Trials
    353. Low Risk of Pneumonia From Pneumocystis jirovecii Infection in Patients With Inflammatory Bowel Disease Receiving Immune Suppression. Clin Gastroenterol Hepatol. 2017 Jun; 15(6):850-856. Cotter TG, Gathaiya N, Catania J, Loftus EV, Tremaine WJ, Baddour LM, Harmsen WS, Zinsmeister AR, Sandborn WJ, Limper AH, Pardi DS. PMID: 28013116; PMCID: PMC5440197.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    354. Development of a Microscopic Colitis Disease Activity Index: a prospective cohort study. Gut. 2018 03; 67(3):441-446. Cotter TG, Binder M, Loftus EV, Abboud R, McNally MA, Smyrk TC, Tremaine WJ, Sandborn WJ, Pardi DS. PMID: 27965284.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    355. Systematic review with meta-analysis: recurrence of Crohn's disease after total colectomy with permanent ileostomy. Aliment Pharmacol Ther. 2017 02; 45(3):381-390. Fumery M, Dulai PS, Meirick P, Farrell AM, Ramamoorthy S, Sandborn WJ, Singh S. PMID: 27928830; PMCID: PMC5253136.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    356. Incidence, Risk Factors, and Outcomes of Colorectal Cancer in Patients With Ulcerative Colitis With Low-Grade Dysplasia: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017 May; 15(5):665-674.e5. Fumery M, Dulai PS, Gupta S, Prokop LJ, Ramamoorthy S, Sandborn WJ, Singh S. PMID: 27916678; PMCID: PMC5401779.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    357. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017 02; 14(2):110-121. Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. PMID: 27899815; PMCID: PMC5550405.
      View in: PubMed   Mentions: 133     Fields:    Translation:Humans
    358. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016 11 17; 375(20):1946-1960. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV, Dieleman LA, Katz S, Rutgeerts P, UNITI–IM-UNITI Study Group. PMID: 27959607.
      View in: PubMed   Mentions: 605     Fields:    Translation:HumansCTClinical Trials
    359. Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy. Aliment Pharmacol Ther. 2017 01; 45(1):50-62. Colombel JF, Jharap B, Sandborn WJ, Feagan B, Peyrin-Biroulet L, Eichner SF, Robinson AM, Mostafa NM, Zhou Q, Thakkar RB. PMID: 27883215; PMCID: PMC5157781.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    360. Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2016 11; 22(11):2711-2723. Ghosh S, Sandborn WJ, Colombel JF, Feagan BG, Panaccione R, Hanauer S, Schreiber S, Peyrin-Biroulet L, Vermeire S, Eichner S, Huang B, Robinson AM, Pappalardo B. PMID: 27585411.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    361. Disease activity indices in coeliac disease: systematic review and recommendations for clinical trials. Gut. 2018 01; 67(1):61-69. Hindryckx P, Levesque BG, Holvoet T, Durand S, Tang CM, Parker C, Khanna R, Shackelton LM, D'Haens G, Sandborn WJ, Feagan BG, Lebwohl B, Leffler DA, Jairath V. PMID: 27799282.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    362. Systematic review: Safety of balloon assisted enteroscopy in Crohn's disease. World J Gastroenterol. 2016 Oct 28; 22(40):8999-9011. Arulanandan A, Dulai PS, Singh S, Sandborn WJ, Kalmaz D. PMID: 27833391; PMCID: PMC5083805.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    363. Development of an index to define overall disease severity in IBD. Gut. 2018 02; 67(2):244-254. Siegel CA, Whitman CB, Spiegel BMR, Feagan B, Sands B, Loftus EV, Panaccione R, D'Haens G, Bernstein CN, Gearry R, Ng SC, Mantzaris GJ, Sartor B, Silverberg MS, Riddell R, Koutroubakis IE, O'Morain C, Lakatos PL, McGovern DPB, Halfvarson J, Reinisch W, Rogler G, Kruis W, Tysk C, Schreiber S, Danese S, Sandborn W, Griffiths A, Moum B, Gasche C, Pallone F, Travis S, Panes J, Colombel JF, Hanauer S, Peyrin-Biroulet L. PMID: 27780886.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    364. Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases. Gastroenterology. 2017 02; 152(2):374-388.e4. Abraham C, Dulai PS, Vermeire S, Sandborn WJ. PMID: 27780712; PMCID: PMC5287922.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCells
    365. Colorectal Cancer and Dysplasia in Inflammatory Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management. Cancer Prev Res (Phila). 2016 Dec; 9(12):887-894. Dulai PS, Sandborn WJ, Gupta S. PMID: 27679553; PMCID: PMC5289746.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    366. Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab. Am J Gastroenterol. 2016 12; 111(12):1806-1815. Osterman MT, Sandborn WJ, Colombel JF, Peyrin-Biroulet L, Robinson AM, Zhou Q, Lewis JD. PMID: 27670599.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    367. Next-Generation Therapeutics for Inflammatory Bowel Disease. Curr Gastroenterol Rep. 2016 Sep; 18(9):51. Dulai PS, Sandborn WJ. PMID: 27461274; PMCID: PMC5901649.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    368. Ozanimod Treatment for Ulcerative Colitis. N Engl J Med. 2016 08 25; 375(8):e17. Sandborn WJ, Feagan BG. PMID: 27557326.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    369. Early remission status predicts long-term outcomes in patients with Crohn's disease treated with certolizumab pegol. Curr Med Res Opin. 2016 12; 32(12):1937-1941. Melmed GY, McGovern D, Schreiber S, Kosutic G, Spearman M, Coarse J, Sandborn WJ. PMID: 27494777.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    370. Endoscopic scoring indices for evaluation of disease activity in Crohn's disease. Cochrane Database Syst Rev. 2016 Aug 08; (8):CD010642. Khanna R, Nelson SA, Feagan BG, D'Haens G, Sandborn WJ, Zou GY, MacDonald JK, Parker CE, Jairath V, Levesque BG. PMID: 27501379; PMCID: PMC7079710.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    371. Evolving Concepts in Phases I and II Drug Development for Crohn's Disease. J Crohns Colitis. 2017 02; 11(2):246-255. Jairath V, Levesque BG, Vande Casteele N, Khanna R, Mosli M, Hindryckx P, Travis S, Duijvestein M, Rimola J, Panes J, D'Haens G, Sandborn WJ, Feagan BG. PMID: 27487793.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    372. Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. Inflamm Bowel Dis. 2016 08; 22(8):1881-6. Bosworth BP, Sandborn WJ, Rubin DT, Harper JR. PMID: 27416045; PMCID: PMC4949012.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    373. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis. 2016 08; 22(8):1870-80. Lee SD, Rubin DT, Sandborn WJ, Randall C, Younes Z, Schreiber S, Schwartz DA, Burakoff R, Binion D, Dassopoulos T, Arsenescu R, Gutierrez A, Scherl E, Kayhan C, Hasan I, Kosutic G, Spearman M, Sen D, Coarse J, Hanauer S. PMID: 27400222; PMCID: PMC4949014.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    374. The Crohn's Disease-Ulcerative Colitis Clinical Appraisal Update: Emerging Trends in Clinical Practice. Clin Gastroenterol Hepatol. 2016 09; 14(9):e121-2. Sandborn W, Colombel JF, D'Haens G, Ghosh S, Panaccione R, Panés J, Travis S, Peyrin-Biroulet L. PMID: 27464592.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    375. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies. J Crohns Colitis. 2017 Jan; 11(1):35-46. Adedokun OJ, Xu Z, Marano CW, Strauss R, Zhang H, Johanns J, Zhou H, Davis HM, Reinisch W, Feagan BG, Rutgeerts P, Sandborn WJ. PMID: 27440869; PMCID: PMC5175493.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCTClinical Trials
    376. Effect of Standardised Scoring Conventions on Inter-rater Reliability in the Endoscopic Evaluation of Crohn's Disease. J Crohns Colitis. 2016 Sep; 10(9):1006-14. Dubcenco E, Zou G, Stitt L, Baker JP, Jeejeebhoy KN, Kandel G, Kim YI, Grover SC, McDonald JW, Shackelton LM, Khanna R, D'Haens G, Sandborn WJ, Feagan BG, Levesque BG. PMID: 27385400.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    377. The Present and Future of Inflammatory Bowel Disease Treatment. Gastroenterol Hepatol (N Y). 2016 Jul; 12(7):438-41. Sandborn WJ. PMID: 27489526; PMCID: PMC4969780.
      View in: PubMed   Mentions: 18  
    378. The Next Wave of Biological Agents for the Treatment of IBD: Evidence from Cochrane Reviews. Inflamm Bowel Dis. 2016 07; 22(7):1737-43. Khanna R, Chande N, Vermeire S, Sandborn WJ, Parker CE, Feagan BG. PMID: 27306074.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    379. The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium. Am J Gastroenterol. 2016 08; 111(8):1147-55. Dulai PS, Singh S, Jiang X, Peerani F, Narula N, Chaudrey K, Whitehead D, Hudesman D, Lukin D, Swaminath A, Shmidt E, Wang S, Boland BS, Chang JT, Kane S, Siegel CA, Loftus EV, Sandborn WJ, Sands BE, Colombel JF. PMID: 27296941.
      View in: PubMed   Mentions: 111     Fields:    Translation:Humans
    380. Randomised clinical trial: a phase 1, dose-ranging study of the anti-matrix metalloproteinase-9 monoclonal antibody GS-5745 versus placebo for ulcerative colitis. Aliment Pharmacol Ther. 2016 07; 44(2):157-69. Sandborn WJ, Bhandari BR, Fogel R, Onken J, Yen E, Zhao X, Jiang Z, Ge D, Xin Y, Ye Z, French D, Silverman JA, Kanwar B, Subramanian GM, McHutchison JG, Lee SD, Shackelton LM, Pai RK, Levesque BG, Feagan BG. PMID: 27218676; PMCID: PMC5089609.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    381. Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results. Clin Gastroenterol Hepatol. 2016 09; 14(9):1302-9. Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Bressler B, Cheifetz AS, Devlin SM, Raffals LE, Vande Casteele N, Mould DR, Colombel JF, Dubinsky M, Sandborn WJ, Siegel CA. PMID: 27189916.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    382. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. N Engl J Med. 2016 May 05; 374(18):1754-62. Sandborn WJ, Feagan BG, Wolf DC, D'Haens G, Vermeire S, Hanauer SB, Ghosh S, Smith H, Cravets M, Frohna PA, Aranda R, Gujrathi S, Olson A, TOUCHSTONE Study Group. PMID: 27144850.
      View in: PubMed   Mentions: 163     Fields:    Translation:HumansCTClinical Trials
    383. Cumulative Length of Bowel Resection in a Population-Based Cohort of Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2016 10; 14(10):1439-44. Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ, Loftus EV. PMID: 27155552; PMCID: PMC5028241.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    384. Cronkhite Canada Syndrome: Significant Response to Infliximab and a Possible Clue to Pathogenesis. Am J Gastroenterol. 2016 05; 111(5):746-8. Boland BS, Bagi P, Valasek MA, Chang JT, Bustamante R, Madlensky L, Sandborn WJ, Harismendy O, Gupta S. PMID: 27151126; PMCID: PMC5824983.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    385. Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 Year. Clin Transl Gastroenterol. 2016 Apr 28; 7:e168. Gibson PR, Feagan BG, Sandborn WJ, Marano C, Strauss R, Johanns J, Padgett L, Collins J, Tarabar D, Hebzda Z, Rutgeerts P, Reinisch W. PMID: 27124701; PMCID: PMC4855165.
      View in: PubMed   Mentions: 17     Fields:    
    386. How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease. Inflamm Bowel Dis. 2016 Apr; 22(4):998-1009. Dulai PS, Singh S, Casteele NV, Boland BS, Sandborn WJ. PMID: 26835982; PMCID: PMC5953904.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    387. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States. Curr Med Res Opin. 2016 07; 32(7):1233-41. Sandborn WJ, Sakuraba A, Wang A, Macaulay D, Reichmann W, Wang S, Chao J, Skup M. PMID: 26986449.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    388. Efficient Early Drug Development for Ulcerative Colitis. Gastroenterology. 2016 05; 150(5):1056-1060. Khanna R, Jairath V, Vande Casteele N, Mosli MH, Zou G, Parker CE, Levesque BG, Sandborn WJ, D'Haens G, Feagan BG. PMID: 27018491.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    389. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. Gastroenterology. 2016 Jun; 150(7):1568-1578. Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, Plevy S, Popp J, Cornillie FJ, Lukas M, Danese S, Gionchetti P, Hanauer SB, Reinisch W, Sandborn WJ, Sorrentino D, Rutgeerts P, PREVENT Study Group. PMID: 26946343.
      View in: PubMed   Mentions: 93     Fields:    Translation:HumansPHPublic Health
    390. Reply. Gastroenterology. 2016 Apr; 150(4):1039. Jharap B, Colombel JF, Sandborn WJ. PMID: 26926449.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    391. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2017 05; 66(5):839-851. Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus EV, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG. PMID: 26893500; PMCID: PMC5531223.
      View in: PubMed   Mentions: 288     Fields:    Translation:Humans
    392. The Crohn's Disease-Ulcerative Colitis Clinical Appraisal. Clin Gastroenterol Hepatol. 2016 Apr; 14(4):638-9. D'Haens G, Bressler B, Danese S, Gibson P, Hanauer SB, Sandborn W. PMID: 26850690.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    393. Integrin-based therapeutics: biological basis, clinical use and new drugs. Nat Rev Drug Discov. 2016 Mar; 15(3):173-83. Ley K, Rivera-Nieves J, Sandborn WJ, Shattil S. PMID: 26822833; PMCID: PMC4890615.
      View in: PubMed   Mentions: 183     Fields:    Translation:HumansAnimalsCells
    394. Systematic Review and Meta-analysis: Placebo Rates in Induction and Maintenance Trials of Ulcerative Colitis. J Crohns Colitis. 2016 May; 10(5):607-18. Jairath V, Zou G, Parker CE, Macdonald JK, Mosli MH, Khanna R, Shackelton LM, Vandervoort MK, AlAmeel T, Al Beshir M, AlMadi M, Al-Taweel T, Atkinson NS, Biswas S, Chapman TP, Dulai PS, Glaire MA, Hoekman D, Koutsoumpas A, Minas E, Samaan MA, Travis S, D'Haens G, Levesque BG, Sandborn WJ, Feagan BG. PMID: 26746169; PMCID: PMC4957452.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    395. Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study. J Crohns Colitis. 2016 Apr; 10(4):418-28. Sandborn WJ, Colombel JF, Ghosh S, Sands BE, Dryden G, Hébuterne X, Leong RW, Bressler B, Ullman T, Lakatos PL, Reinisch W, Xu LA, Luo A. PMID: 26721935; PMCID: PMC4946756.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    396. Validation of the Inflammatory Bowel Disease Disability Index in a population-based cohort. Gut. 2017 04; 66(4):588-596. Gower-Rousseau C, Sarter H, Savoye G, Tavernier N, Fumery M, Sandborn WJ, Feagan BG, Duhamel A, Guillon-Dellac N, Colombel JF, Peyrin-Biroulet L, International Programme to Develop New Indexes for Crohn's Disease (IPNIC) group, International Programme to Develop New Indexes for Crohn's Disease (IPNIC) group. PMID: 26646934.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    397. New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us? Inflamm Bowel Dis. 2015 Dec; 21(12):2948-57. Chande N, Marshall JK, Seow CH, Sandborn WJ, Parker CE, Nelson S, Feagan BG. PMID: 26540276.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    398. The Role of Psychosocial Care in Adapting to Health Care Reform. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2219-24. Reiss M, Sandborn WJ. PMID: 26589873.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    399. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2015 Nov 23; (11):CD001176. Singh S, Stroud AM, Holubar SD, Sandborn WJ, Pardi DS. PMID: 26593456; PMCID: PMC4917283.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    400. Magnetic resonance enterography is feasible and reliable in multicenter clinical trials in patients with Crohn's disease, and may help select subjects with active inflammation. Aliment Pharmacol Ther. 2016 Jan; 43(1):61-72. Coimbra AJ, Rimola J, O'Byrne S, Lu TT, Bengtsson T, de Crespigny A, Luca D, Rutgeerts P, Bruining DH, Fidler JL, Sandborn WJ, Santillan CS, Higgins PD, Al-Hawary MM, Vermeire S, Vanbeckevoort D, Vanslembrouck R, Peyrin-Biroulet L, Laurent V, Herrmann KA, Panes J. PMID: 26548868.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    401. Pseudomonas Meningitis During Vedolizumab Therapy for Crohn's Disease. Am J Gastroenterol. 2015 Nov; 110(11):1631-2. Boland BS, Dulai PS, Chang M, Sandborn WJ, Levesque BG. PMID: 26618431; PMCID: PMC5824985.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    402. Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis. Gastroenterology. 2016 Feb; 150(2):477-87.e9. Tew GW, Hackney JA, Gibbons D, Lamb CA, Luca D, Egen JG, Diehl L, Eastham Anderson J, Vermeire S, Mansfield JC, Feagan BG, Panes J, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, Kirby JA, Irving PM, De Hertogh G, Van Assche GA, Rutgeerts P, O'Byrne S, Hayday A, Keir ME. PMID: 26522261.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    403. Development and validation of a histological index for UC. Gut. 2017 01; 66(1):50-58. Mosli MH, Feagan BG, Zou G, Sandborn WJ, D'Haens G, Khanna R, Shackelton LM, Walker CW, Nelson S, Vandervoort MK, Frisbie V, Samaan MA, Jairath V, Driman DK, Geboes K, Valasek MA, Pai RK, Lauwers GY, Riddell R, Stitt LW, Levesque BG. PMID: 26475633.
      View in: PubMed   Mentions: 105     Fields:    Translation:Humans
    404. Central Reading of Endoscopy Endpoints in Inflammatory Bowel Disease Trials. Inflamm Bowel Dis. 2015 Oct; 21(10):2475-82. Gottlieb K, Travis S, Feagan B, Hussain F, Sandborn WJ, Rutgeerts P. PMID: 26086596.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    405. Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease. Aliment Pharmacol Ther. 2015 Nov; 42(10):1170-81. Feagan BG, Sandborn WJ, D'Haens G, Lee SD, Allez M, Fedorak RN, Seidler U, Vermeire S, Lawrance IC, Maroney AC, Jurgensen CH, Heath A, Chang DJ. PMID: 26400458.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    406. Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials. Aliment Pharmacol Ther. 2015 Nov; 42(10):1200-10. Jairath V, Khanna R, Zou GY, Stitt L, Mosli M, Vandervoort MK, D'Haens G, Sandborn WJ, Feagan BG, Levesque BG. PMID: 26388424.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    407. Budesonide Foam Has a Favorable Safety Profile for Inducing Remission in Mild-to-Moderate Ulcerative Proctitis or Proctosigmoiditis. Dig Dis Sci. 2015 Nov; 60(11):3408-17. Rubin DT, Sandborn WJ, Bosworth B, Zakko S, Gordon GL, Sale ME, Rolleri RL, Golden PL, Barrett AC, Bortey E, Forbes WP. PMID: 26386854; PMCID: PMC4621699.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    408. Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial. Gastroenterology. 2016 Jan; 150(1):96-102. Sandborn WJ, Panés J, Zhang H, Yu D, Niezychowski W, Su C. PMID: 26376350.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    409. IOIBD technical review on endoscopic indices for Crohn's disease clinical trials. Gut. 2016 09; 65(9):1447-55. Vuitton L, Marteau P, Sandborn WJ, Levesque BG, Feagan B, Vermeire S, Danese S, D'Haens G, Lowenberg M, Khanna R, Fiorino G, Travis S, Mary JY, Peyrin-Biroulet L. PMID: 26353983.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    410. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet. 2015 Nov 07; 386(10006):1825-34. Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, Panaccione R, Bitton A, Paré P, Vermeire S, D'Haens G, MacIntosh D, Sandborn WJ, Donner A, Vandervoort MK, Morris JC, Feagan BG, REACT Study Investigators. PMID: 26342731.
      View in: PubMed   Mentions: 145     Fields:    Translation:Humans
    411. Randomised clinical study: discrepancies between patient-reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis. Aliment Pharmacol Ther. 2015 Nov; 42(9):1082-92. Jharap B, Sandborn WJ, Reinisch W, D'Haens G, Robinson AM, Wang W, Huang B, Lazar A, Thakkar RB, Colombel JF. PMID: 26381802; PMCID: PMC5049645.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    412. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015 Sep; 110(9):1324-38. Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF. PMID: 26303131.
      View in: PubMed   Mentions: 595     Fields:    Translation:Humans
    413. Systematic review with meta-analysis: faecal diversion for management of perianal Crohn's disease. Aliment Pharmacol Ther. 2015 Oct; 42(7):783-92. Singh S, Ding NS, Mathis KL, Dulai PS, Farrell AM, Pemberton JH, Hart AL, Sandborn WJ, Loftus EV. PMID: 26264359; PMCID: PMC6698449.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    414. Reply: To PMID 24036054. Clin Gastroenterol Hepatol. 2015 Dec; 13(13):2382. Sandborn WJ, Bouguen G. PMID: 26247165.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    415. Agreement of site and central readings of ileocolonoscopic scores in Crohn's disease: comparison using data from the EXTEND trial. Gastrointest Endosc. 2016 Jan; 83(1):188-97.e1-3. Rutgeerts P, Reinisch W, Colombel JF, Sandborn WJ, D'Haens G, Petersson J, Zhou Q, Iezzi A, Thakkar RB. PMID: 26234693.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    416. Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis. Aliment Pharmacol Ther. 2015 Sep; 42(5):504-14. Rutgeerts P, Feagan BG, Marano CW, Padgett L, Strauss R, Johanns J, Adedokun OJ, Guzzo C, Zhang H, Colombel JF, Reinisch W, Gibson PR, Sandborn WJ, PURSUIT-IV study group. PMID: 26119226; PMCID: PMC4755132.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    417. Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis. J Crohns Colitis. 2015 Sep; 9(9):738-46. Lichtenstein GR, Travis S, Danese S, D'Haens G, Moro L, Jones R, Huang M, Ballard ED, Bagin R, Hardiman Y, Collazo R, Sandborn WJ. PMID: 26094251; PMCID: PMC4736820.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    418. IBD: Indication extrapolation for anti-TNF biosimilars. Nat Rev Gastroenterol Hepatol. 2015 Jul; 12(7):373-4. Vande Casteele N, Sandborn WJ. PMID: 26077557.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    419. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):348-354.e17. Peyrin-Biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, Colombel JF, Hanauer SB, Rycroft B. PMID: 26071941.
      View in: PubMed   Mentions: 125     Fields:    Translation:Humans
    420. Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study. Aliment Pharmacol Ther. 2015 Aug; 42(3):330-42. Sandborn WJ, Melmed GY, McGovern DP, Loftus EV, Choi JM, Cho JH, Abraham B, Gutierrez A, Lichtenstein G, Lee SD, Randall CW, Schwartz DA, Regueiro M, Siegel CA, Spearman M, Kosutic G, Pierre-Louis B, Coarse J, Schreiber S. PMID: 26031921.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    421. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis. 2015 Jun; 21(6):1329-40. Panaccione R, Sandborn WJ, Gordon GL, Lee SD, Safdi A, Sedghi S, Feagan BG, Hanauer S, Reinisch W, Valentine JF, Huang B, Carcereri R. PMID: 25989338; PMCID: PMC4450894.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    422. Biologic concentration testing in inflammatory bowel disease. Inflamm Bowel Dis. 2015 Jun; 21(6):1435-42. Vaughn BP, Sandborn WJ, Cheifetz AS. PMID: 25590953; PMCID: PMC4437804.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    423. Assessment of mucosal healing in inflammatory bowel disease: review. Gastrointest Endosc. 2015 Aug; 82(2):246-55. Dulai PS, Levesque BG, Feagan BG, D'Haens G, Sandborn WJ. PMID: 26005012; PMCID: PMC6709676.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    424. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther. 2015 Jul; 42(2):188-202. Rosario M, Dirks NL, Gastonguay MR, Fasanmade AA, Wyant T, Parikh A, Sandborn WJ, Feagan BG, Reinisch W, Fox I. PMID: 25996351; PMCID: PMC5032981.
      View in: PubMed   Mentions: 102     Fields:    Translation:HumansCTClinical Trials
    425. C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2015 Jun; 110(6):802-19; quiz 820. Mosli MH, Zou G, Garg SK, Feagan SG, MacDonald JK, Chande N, Sandborn WJ, Feagan BG. PMID: 25964225.
      View in: PubMed   Mentions: 213     Fields:    Translation:Humans
    426. The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]. J Crohns Colitis. 2015 Aug; 9(8):607-16. Travis SP, Schnell D, Feagan BG, Abreu MT, Altman DG, Hanauer SB, Krzeski P, Lichtenstein GR, Marteau PR, Mary JY, Reinisch W, Sands BE, Schnell P, Yacyshyn BR, Colombel JF, Bernhardt CA, Sandborn WJ. PMID: 25956538; PMCID: PMC4584567.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    427. Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease. Gut. 2016 07; 65(7):1119-25. Khanna R, Zou G, D'Haens G, Rutgeerts P, McDonald JW, Daperno M, Feagan BG, Sandborn WJ, Dubcenco E, Stitt L, Vandervoort MK, Donner A, Luo A, Levesque BG. PMID: 25935574.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    428. New Targets for Small Molecules in Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y). 2015 May; 11(5):338-40. Sandborn WJ. PMID: 27482177; PMCID: PMC4962684.
      View in: PubMed   Mentions: 5  
    429. Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn's Disease: An IOIBD Initiative. J Crohns Colitis. 2015 Aug; 9(8):601-6. Danese S, Fiorino G, Mary JY, Lakatos PL, D'Haens G, Moja L, D'Hoore A, Panes J, Reinisch W, Sandborn WJ, Travis SP, Vermeire S, Peyrin-Biroulet L, Colombel JF. PMID: 25908718.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    430. Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease. J Clin Pharmacol. 2015 Aug; 55(8):866-74. Wade JR, Parker G, Kosutic G, Feagen BG, Sandborn WJ, Laveille C, Oliver R. PMID: 25735646; PMCID: PMC6680228.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    431. Photodynamic therapy as a new treatment modality for inflammatory and infectious conditions. Expert Rev Clin Immunol. 2015 May; 11(5):637-57. Reinhard A, Sandborn WJ, Melhem H, Bolotine L, Chamaillard M, Peyrin-Biroulet L. PMID: 25837708.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    432. Vedolizumab for the treatment of moderately to severely active ulcerative colitis. Pharmacotherapy. 2015 Apr; 35(4):412-23. Dulai PS, Mosli M, Khanna R, Levesque BG, Sandborn WJ, Feagan BG. PMID: 25884529; PMCID: PMC6709861.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    433. Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC. Inflamm Bowel Dis. 2015 Mar; 21(3):606-14. Bouguen G, Sninsky C, Tang KL, Colombel JF, D'Haens G, Kornbluth A, Mantzaris GJ, Rachmilewitz D, Reinisch W, Rutgeerts P, Molenda M, Jannekevan der Woude C, Sandborn WJ. PMID: 25581826.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    434. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis. Aliment Pharmacol Ther. 2015 Apr; 41(8):734-46. Colombel JF, Reinisch W, Mantzaris GJ, Kornbluth A, Rutgeerts P, Tang KL, Oortwijn A, Bevelander GS, Cornillie FJ, Sandborn WJ. PMID: 25728587.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    435. Emerging Treatment Options in Mild to Moderate Ulcerative Colitis. Gastroenterol Hepatol (N Y). 2015 Mar; 11(3 Suppl 1):1-16. Lichtenstein GR, Hanauer SB, Sandborn WJ. PMID: 26491415; PMCID: PMC4609145.
      View in: PubMed   Mentions: 3  
    436. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature. 2015 Mar 05; 519(7541):57-62. Taniguchi K, Wu LW, Grivennikov SI, de Jong PR, Lian I, Yu FX, Wang K, Ho SB, Boland BS, Chang JT, Sandborn WJ, Hardiman G, Raz E, Maehara Y, Yoshimura A, Zucman-Rossi J, Guan KL, Karin M. PMID: 25731159; PMCID: PMC4447318.
      View in: PubMed   Mentions: 326     Fields:    Translation:HumansAnimalsCells
    437. Introducing vedolizumab to clinical practice: who, when, and how? J Crohns Colitis. 2015 Apr; 9(4):356-66. Bryant RV, Sandborn WJ, Travis SP. PMID: 25687206.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    438. Immunodeficiency and autoimmune enterocolopathy linked to NFAT5 haploinsufficiency. J Immunol. 2015 Mar 15; 194(6):2551-60. Boland BS, Widjaja CE, Banno A, Zhang B, Kim SH, Stoven S, Peterson MR, Jones MC, Su HI, Crowe SE, Bui JD, Ho SB, Okugawa Y, Goel A, Marietta EV, Khosroheidari M, Jepsen K, Aramburu J, López-Rodríguez C, Sandborn WJ, Murray JA, Harismendy O, Chang JT. PMID: 25667416; PMCID: PMC4355235.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansAnimalsCells
    439. Validation of gene expression biomarker analysis for biopsy-based clinical trials in Crohn's disease. Inflamm Bowel Dis. 2015 Feb; 21(2):323-30. Boland BS, Boyle DL, Sandborn WJ, Firestein GS, Levesque BG, Hillman J, Zhang B, Proudfoot J, Eckmann L, Ernst PB, Rivera-Nieves J, Pola S, Copur-Dahi N, Zou G, Chang JT. PMID: 25545378; PMCID: PMC4404151.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    440. Budesonide foam induces remission in patients with mild to moderate ulcerative proctitis and ulcerative proctosigmoiditis. Gastroenterology. 2015 Apr; 148(4):740-750.e2. Sandborn WJ, Bosworth B, Zakko S, Gordon GL, Clemmons DR, Golden PL, Rolleri RL, Yu J, Barrett AC, Bortey E, Paterson C, Forbes WP. PMID: 25644096.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    441. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials. Dig Liver Dis. 2015 May; 47(5):356-64. Lopez A, Ford AC, Colombel JF, Reinisch W, Sandborn WJ, Peyrin-Biroulet L. PMID: 25661014.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    442. Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies. Aliment Pharmacol Ther. 2015 Mar; 41(5):409-18. Sandborn WJ, Danese S, D'Haens G, Moro L, Jones R, Bagin R, Huang M, David Ballard E, Masure J, Travis S. PMID: 25588902; PMCID: PMC6681012.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    443. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015 Jan; 21(1):182-97. Papamichael K, Gils A, Rutgeerts P, Levesque BG, Vermeire S, Sandborn WJ, Vande Casteele N. PMID: 25222660.
      View in: PubMed   Mentions: 86     Fields:    Translation:Humans
    444. Tailoring treatment to the individual patient: drug monitoring. Dig Dis. 2014; 32 Suppl 1:88-91. Sandborn WJ. PMID: 25531358.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    445. Assessment of histologic disease activity in Crohn's disease: a systematic review. Inflamm Bowel Dis. 2014 Nov; 20(11):2092-103. Mojtahed A, Khanna R, Sandborn WJ, D'Haens GR, Feagan BG, Shackelton LM, Baker KA, Dubcenco E, Valasek MA, Geboes K, Levesque BG. PMID: 25137418.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimals
    446. Tumor necrosis factor-alpha antagonists twenty years later: what do Cochrane reviews tell us? Inflamm Bowel Dis. 2014 Nov; 20(11):2132-41. Akobeng AA, Sandborn WJ, Bickston SJ, Chande N, Shackelton LM, Nelson S, Feagan BG. PMID: 25299543.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    447. Proactive therapeutic concentration monitoring of infliximab may improve outcomes for patients with inflammatory bowel disease: results from a pilot observational study. Inflamm Bowel Dis. 2014 Nov; 20(11):1996-2003. Vaughn BP, Martinez-Vazquez M, Patwardhan VR, Moss AC, Sandborn WJ, Cheifetz AS. PMID: 25192499; PMCID: PMC5557346.
      View in: PubMed   Mentions: 87     Fields:    Translation:Humans